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Although caused by distinct genetic mutations, the peroxisomal disorders X-linked 
adrenoleukodystrophy (X-ALD), pseudoneonatal adrenoleukodystrophy (pseudo 
NALD), and neonatal adrenoleukodystrophy (NALD) share several disease hallmarks. 
Strikingly, the underlying dysfunctions are either related to generalized peroxisomal 
defects or to defects in peroxisomal β-oxidation. In contrast, leukodystrophy is not a 
feature of other peroxisomal disorders e.g. in α-oxidation or plasmalogen-synthesis 
defects. This indicates a common pathomechanism for β-oxidation and generalized 
peroxisomal defects. Further indications for this derive from mice lacking complete pe-
roxisomal function only in oligodendrocytes. The pattern of inflammatory subcortical 
demyelination in these CnpCre/Wt*Pex5-/- mutants is reminiscent of the cerebral patholo-
gy known from X-ALD patients lacking peroxisomal β-oxidation of very long chain fatty 
acids. This led to the hypothesis that impaired β-oxidation may culminate in secondary 
loss of further peroxisomal functions. So far, several mouse models with defective pe-
roxisomal β-oxidation were generated, but failed to develop cerebral demyelination. In 
search for an appropriate model with impaired peroxisomal β-oxidation to investigate 
possible secondary peroxisomal defects and subsequent pathology, aged 
CnpCre/Wt*Mfp2-/- mice were analyzed. Indeed, CnpCre/Wt*Mfp2-/- mice developed demye-
linating lesions in the frontal corpus callosum when aged ≥ 16 months. This was ac-
companied by reactive gliosis, lymphocyte infiltration, and behavioral alterations. Thus 
CnpCre/Wt*Mfp2-/- mice proved to be suitable to study demyelination and possibly pre-
ceding effects of impaired peroxisomal β-oxidation on peroxisomes. To facilitate oli-
godendrocyte specific analysis of oligodendroglial peroxisomes novel transgenic mice 
with fluorescently labeled peroxisomes in oligodendrocytes (Cnp-mEos2-PTS1) were 
generated. Employing a photo-convertible fluorescent protein enabled ‘pulse-chase’ 
experiments to provide insight into peroxisomal biogenesis and degradation. Brain sec-
tions from double-transgenic Cnp-mEos2-PTS1*CnpCre/Wt*Mfp2-/- mice revealed a pro-
gressively decreasing number and increased size of peroxisomes. Alterations were 
observed already at 2 months, preceding disease onset by approximately one year. At 
16 months of age only 50% of peroxisomes were preserved. In vitro experiments using 
primary MFP2-deficient oligodendrocytes proved a dramatically reduced peroxisomal 
turnover by both, decreased degradation of pulse-labeled peroxisomes, i.e. enhanced 
organelle aging, and diminished appearance of new peroxisomes. The mechanism of 
this decreased organelle turnover remains elusive. Interestingly, inhibiting pexophagy 
in control oligodendrocytes by use of 3-Methyladenine also blocked peroxisomal bio-
genesis, which indicates tight coupling between peroxisomal biogenesis and degrada-
tion. Together the data suggest that perturbation of peroxisomal β-oxidation in oli-
godendrocytes causes secondary impairment of peroxisomal functions, which 
precedes and possibly triggers cerebral demyelination. 




1.1 Peroxisomes  
In an electron microscopic study in 1954 Johannes Rhodin observed small, single 
membrane bounded structures, which he referred to as microbodies (Rhodin 1954). 
After the discovery of hydrogen peroxide producing and degrading enzymes in their 
matrix, microbodies were termed peroxisomes (De Duve & Baudhuin 1966). Peroxi-
somes are ubiquitous organelles throughout the eukaryote domain and are found in all 
nucleated mammalian cells (Lazarow & Fujiki 1985). Not only the peroxisomal number, 
but also their size varies considerably between cell types. In the mammalian brain pe-
roxisomes can be as small as 0.1 µm in diameter, whereas in liver they can measure 
up to 1 µm (Colton 2004). They are abundant in liver and brain. In the latter they are 
especially numerous in glial cells, such as oligodendrocytes and astrocytes (Troffer-
Charlier et al. 1998). The significance of peroxisomes for normal development and 
maintenance has been shown by the identification of severe diseases related to perox-
isomal biogenesis or single enzyme defects. 
 
1.1.1 Peroxisomal metabolism and its biological importance  
At least 50 proteins with well-established enzymatic activity have been identified in the 
peroxisomal matrix, of which more than half participate in lipid metabolism. Moreover, 
enzymes with unknown functions have been described, as well as enzymatic reactions 
that could not yet be ascribed to specific proteins (Wanders & Waterham 2006). Apart 
from luminal enzymes, peroxisomes contain specific integral membrane proteins such 
as substrate transporters and proteins for peroxisomal matrix protein import (Heiland & 
Erdmann 2005).  
Peroxisomes play an essential role in a number of catabolic reactions, such as the β-
oxidation of very long-chain fatty acids (VLCFA; > 22 carbon atoms), branched-chain 
FA, monounsaturated FA, polyunsaturated FA, and their derivatives, the eicosanoides 
and docosanoids. α-oxidation occurs exclusively in peroxisomes, as well as certain 
steps of purine-, polyamine-, D-amino acid, ethanol, vitamin E and K, and cholesterol 
degradation (Fig. 1; Wanders & Waterham, 2006). In yeast and plants peroxisomes are 
the sole location of β-oxidation, whereas in higher eukaryotes they complement mito-
chondrial degradation of short to long chain fatty acids, as the sole site for VLCFA deg-
radation. In contrast to mitochondria, peroxisomal β-oxidation of acyl-CoA to enoyl-CoA 
by acyl-coenzyme A oxidase (ACOX) results in the formation of H2O2, which requires 
detoxification by intraperoxisomal catalase. During mitochondrial acyl-CoA oxidation, 
FAD is reduced to FADH2 providing protons for the respiratory chain. In peroxisomes 
enoyl-CoA is further hydrated and subsequently oxidized by the multifunctional Protein 
2 (MFP2), also called D-bifunctional Protein (DBP), before a thiolytic cleavage cata-
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lyzed by the acetyl-CoA acyltransferase 1 (ACAA1) releases a shortened FA and an 
acetyl-CoA. MFP2 also accepts branched chain FA as substrates. FA undergo β-
oxidation until the formation of octanoyl-CoA, which cannot further be degraded in pe-
roxisomes. Resulting acetyl-CoAs and octanoyl-CoAs are carnitylated and exported for 
degradation and ATP production in mitochondria (Lazarow 1978; Wanders 2014). 
Substrates for β-oxidation are transported across the peroxisomal membrane as acti-
vated CoA esters by one of three ATP-binding cassette transporters subtype D 
(ABCD1; ABCD2; ABCD3; Theodoulou et al. 2006). In addition, diffusion of free fatty 
acids across membranes has been described (Pillai et al. 2009).  
Besides catabolic reactions peroxisomes participate in a number of anabolic reactions 
including elongation of FA, formation of bile acid, and polyunsaturated FA, e.g do-
cosahexaenoic acid (DHA; C24:6), which is an abundant polyunsaturated FA in the 
brain (Wanders & Waterham 2006; Jing & Lim 2012; Itoyama et al. 2012). Furthermore, 
indications for involvement in cholesterol biosynthesis have been found (Smith & Ait-
chison 2013).  
In the liver peroxisomes are of vital importance. Apart from participating in the for-
mation of bile acids they are involved in the degradation of various toxins. About 25% 
of the ingested ethanol is degraded by liver peroxisomes (Alberts et al. 2002). Moreo-
ver, peroxisomes are crucial for proper brain function, especially for myelin, an ex-
tremely lipid rich structure that enwraps neuronal processes. Peroxisomal metabolites 
participate in the formation of several plasma membrane lipid classes. Sphingolipids, 
form the head group of phospholipids and glycolipids, which are major membrane 
components. They contain long chain and very long chain FA, mostly C24:0 and C24:1. 
The latter are exclusive peroxisomal metabolites (Joseph et al. 1972). Plasmalogens 
form part of the glycerophospholipids, which constitute the biggest fraction of phospho-
lipids in the brain, especially in myelin (Yanagihara & Cumings 1969; Thomas et al. 
1990; Farooqui et al. 2000). The first steps of plasmalogen synthesis are mediated by 
the peroxisomal enzymes glyceronephosphate O-acyltransferase and alkylglycerone 
phosphate synthase and their loss of function results in a serve disorder in humans, 
Chondrodysplasia punctata (Hardeman & van den Bosch 1991; Hajra 1997). Apart 
from their importance for membrane dynamics plasmalogens serve as a reservoir for 
secondary messengers (Brites et al. 2008). Cholesterol, which can be degraded and 
likely partly be synthesized in peroxisomes, belongs to another main component of 
plasma membranes, the sterols.  
Recently reactive oxygen species (ROS) and reactive nitrogen species (RNS) lost their 
oath as purely toxic byproducts of cellular metabolism and have become acknowledged 
as intracellular messengers, if present in subtoxic concentrations (Fransen et al. 2012). 
They have been implicated in the regulation of cell proliferation, gene expression and 
programmed cell death (Scherz-Shouval & Elazar 2011). Furthermore, redox signaling 
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can be mediated by ROS and RNS oxidation of cysteine residues, which influences the 
enzymatic activity of proteins. (Barford 2004). Peroxisomes as platforms of abundant 
ROS and RNS generation likely play an important role not only in ROS detoxification, 
but as well in redox signaling. In rat liver 35% of all H2O2 generated is derived from 
peroxisomal oxidases (Boveris et al. 1972). Imbalanced peroxisomal metabolism thus 
may lead to a failure in redox signaling and to increased oxidative stress as observed 
in peroxisome related diseases (Galino et al. 2011).  
Peroxisomes malfunction has been associated with inflammatory processes by ROS 
production, but also other peroxisomal products like plasmalogen and DHA serve as 
precursors for bioactive molecules involved in inflammation, e.g. leukotrienes, prosta-
glandins, and eicosanoids (Braverman & Moser 2012). Moreover, eicosanoids are de-
graded in peroxisomes and play a critical role in inflammatory reactions (Funk 2001).  
 
Fig.  I: A schematic view of main metabolic pathways in peroxisomes  
Enzymes are accentuated by colored boxes according to the different pathways. While enzymes of the 
Peroxisomal β-oxidation are highlighted in light orange, α-oxidation enzymes are shown in yellow and 
enzymes involved in bile acid synthesis are depicted in light and dark orange. The different types of sub-
strates for the β-oxidation are indicated by distinct colors. Abbreviations not mentioned in the text: AGPS = 
alkyl-dihydroxyacetonephosphate synthase, AMACR = 2-methylacyl-CoA racemace, BAAT = bile acid–
CoA:amino acid N-acyltransferase, brAcyl = branched-acyl, CA = cholic acid, CAT = catalase, CDCA = 
chenodeoxycholic acid, DCA = dicarboxylic acids, DHAP = dihydroxyacetone phosphate, DHCA = dihy-
droxycholestanoic acid, FAR1 = fatty acyl reductase 1, HACL1 = 2-hydroxyphytanoyl-CoA lyase, LBP = L-
bifunctional protein, PHYH = phytanoyl-CoA 2-hydoxylase, PrDH = pristanal dehydrogenase, SCPx = 
sterol carrier protein X, THCA = trihydroxycholestanoic acid (Adapted from Waterham et al., 2016) 
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1.1.2 Brain Peroxisomes 
Peroxisomes are involved in the degradation and formation of several metabolites that 
are highly abundant in the brain. Brain peroxisomes are strikingly smaller than in liver 
or other tissues. Whereas liver peroxisomes measure between 0.3 and 0.9 µm in di-
ameter, peroxisomes in astrocytes and oligodendrocytes have been found to measure 
about 0.2 µm and 0.05-0.1 µm, respectively and are thus termed microperoxisomes 
(McKenna et al. 1976; Colton 2004; Kassmann et al. 2011). Peroxisomes are found in 
all CNS cell types, but interestingly peroxisomes in white matter tracts are frequently 
associated with the cytoplasmic regions of oligodendrocytes rather than with axons. In 
neurons peroxisomes are mostly detected in the cell soma (Ahlemeyer et al. 2007; 
Kassmann et al. 2011). In myelin preparations it was shown that the peroxisomal pro-
tein content differs between CNS cell types. Pex5 and Pex14, both peroxins involved in 
peroxisome protein import, were much more abundant in total brain lysate than in mye-
lin enriched fractions. Contrariwise, Pex11β and catalase were enriched in myelin pe-
roxisomes (Kassmann et al. 2011; and unpublished data). The contribution of peroxi-
somal metabolism to proper brain function is highlighted by severe CNS pathology 
seen in peroxisomal disorders patients. Furthermore, impaired myelination and demye-
lination in Zellweger syndrome spectrum patients emphasize the importance of peroxi-
somes for myelin.  
 
1.2 Peroxisomal biogenesis  
Several proteins, so-called peroxins (PEX), are essential for peroxisome assembly and 
maintenance (Kiel et al. 2006). They enable the targeting and insertion of peroxisomal 
membrane and matrix proteins, as well as the biogenesis of peroxisomes via de novo 
synthesis or through growth and division of preexisting peroxisomes. Lack of certain 
peroxins can either result in the total absence of peroxisomes or in the formation of 
dysfunctional peroxisomal ‘ghosts’, if the import of matrix proteins is impaired.  
 
1.2.1 Matrix protein import  
Different from mitochondria peroxisomes do not contain DNA. Peroxisomal proteins are 
encoded in the nucleus and synthesized on free ribosomes in the cytoplasm. Two dif-
ferent classes of peroxisomal targeting sequences (PTS) label proteins for peroxisomal 
import. Most proteins contain the C-terminal target sequence type 1 (PTS1), consisting 
of the three amino acids Ser-Lys-Leu (SKL) or conserved variants (S/A/C-K/R/H-L; 
Gould et al. 1989). Different targeting sequences can vary in their efficacy of peroxiso-
mal targeting. A well known example is catalase, which contains a weak peroxisomal 
targeting signal, the tetrapeptide KANL. PTS1 is recognized by the cytosolic recycling 
receptor Pex5. The Pex5-cargo complex interacts with the importomer on the peroxi-
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somal membrane consisting of a docking complex and the RING-finger complex. The 
former is composed of PEX14, PEX13 and PEX17 (Fig. 2; Lazarow & Fujiki 1985; Léon 
et al. 2006; Brocard & Hartig 2014). PEX5 binds to PEX14 and PEX13, which likely 
results in the formation of an aqueous pore that allows protein translocation of fully 
folded proteins (Meinecke et al. 2010). After cargo release into the peroxisomal matrix, 
a process that is not fully understood yet, PEX5 is mono-ubiquitinated by the RING-
finder complex and exported to the cytoplasm via the ATPases PEX1 and PEX6 (Car-
valho et al. 2007). In the cytosol the ubiquitin moiety is rapidly removed and PEX5 can 
enter the next round of protein import (Grou et al. 2008; 2012). 
Many proteins carrying PTS1 sequences have been identified so far, but recently addi-
tional proteins with PTS1 sequences located downstream of a stop codon were en-
countered. Only by translational read through of the original stop codon a peroxisomal 
targeting sequence is appended to these proteins as e.g. in about 1.6% of transcribed 
lactate dehydrogenase B (LDHB), which normally localizes to mitochondria (Schueren 
et al. 2014). Moreover, PEX5 protein import has lately been described to be redox sen-
sitive. Under increased oxidative stress and in aged cells, PEX5 accumulates on the 
peroxisomal membrane and peroxisomal protein import is decreased (Apanasets et al. 
2013).  
PTS2 consists of a N-terminally located nonapeptide with the consensus sequence 
(R/K)-(L/V/I/Q)-XX-(L/V/I/H)-(L/S/G/A)-X-(H/Q)-(L/A) and is recognized by PEX7, which 
interacts with co-receptors PEX5L, a splice variant of PEX5 (Swinkels et al. 1991; Mar-
zioch et al. 1994). Formerly, it was assumed that PTS2 proteins are imported via the 
same import machinery as PTS1 proteins. However, Montilla-Martinez and colleagues 
recently encountered a pore formed by the PTS2 co-receptor Pex18 and the docking 
complex PEX14 and PEX17 (Montilla-Martinez et al. 2015). A minor portion of proteins 
without PTS reach the peroxisomal lumen by association to PTS1 or PTS2 containing 
proteins in a so-called piggy-back mechanism.  
 




Fig.  II: Import of peroxisomal proteins containing a PTS1 
The cargo (C) is recognized in the cytosol by PEX5, which subsequently interacts with the docking com-
plex consisting of peroxins 13, 14 and 17 to form a transient pore. After cargo release in the peroxisomal 
lumen PEX5 is ubiquitinated (Ub) by the Ring-finger complex (PEX 2, 10, 12), E2 ubiquitin-conjugating 
enzyme (PEX4) and the ubiquitin-protein transferase activating protein (PEX22). The receptor release is 
mediated via the ATPases PEX1 and 6 (Adapted from Meinecke et al., 2016). 
 
1.2.2 Insertion of peroxisomal membrane proteins 
Protein insertion into the peroxisomal membrane is mediated by PEX3, PEX16, and 
PEX19. Loss of any of these three peroxins results in the absence of detectable perox-
isomal structures (Matsuzono et al. 1999; Fang et al. 2004). PEX19 is a predominantly 
cytosolic receptor, which recognizes membrane peroxisome targeting sequences 
(mPTS) and serves as a chaperon for the hydrophilic PMPs in the cytosol (Shibata et 
al. 2004). PEX3 and PEX16 are integral membrane proteins. A broad range of peroxi-
somal membrane proteins (PMP) contain mPTSs, which consists of up to two trans-
membrane segments interspersed with positively charged amino acid residues (Dyer et 
al. 1996; Brosius et al. 2002). This group of proteins is defined as class I PMPs, in con-
trary to class II PMPs, which do not interact with PEX19 for peroxisomal targeting 
(Theodoulou et al. 2006). Class I PMPs bind to the C-terminal region of PEX19 in the 
cytosol. The receptor-cargo complex subsequently docks to PEX3 in the peroxisomal 
membrane via the N-terminus. It is speculated that PEX3 perturbs the peroxisomal 
membrane and thereby facilitates PMP insertion (Pinto et al. 2009). In mammalian cells 
PEX16, which like PEX3 is a class II PMP, presumably acts as a receptor for both 
PEX3 and PEX19 (Kim 2006).  
Besides the classical class I pathway, class II PMPs have been observed to traffic to 
peroxisomes via the ER (Geuze et al. 2003). By the insertion of PMPs into the ER spe-
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cialized subdomains can be formed, which are referred to as peroxisomal ER (pER), 
(Lam et al. 2011; Agrawal et al. 2011). In yeast it has been shown that a part of the 
machinery involved in the secretory pathway, the Sec61 translocon and the GET ma-
chinery, participate in class II PMP insertion into the ER (van der Zand et al. 2010; 
Thoms et al. 2012). Little is known about the signals necessary for PMP sorting into 
specialized ER domains. Recently an N-terminal 17 amino acid segment was identified 
in Pex3p that is necessary and sufficient for intra-ER sorting (Fakieh et al. 2013). Exit 
of preperoxisomal vesicles is independent of COPII, a protein involved in ER vesicle 
budding, but it involves PEX3 and PEX19, proteins not related to secretion so far 
(Sacksteder et al. 2000; South et al. 2000).  
In vitro studies using mammalian cells have shown that PEX16 targets to peroxisomes 
and to the ER where it can mediate insertion of several PMPs (Kim 2006; Toro et al. 
2009; Aranovich et al. 2014). Direct insertion of PMP into peroxisomes or indirect traf-
ficking via the ER are not mutually exclusive. Apart from PEX16 also PEX3 and PMP34 
have been described to reach peroxisomal localization via both pathways (Aranovich et 
al. 2014). PEX16 furthermore is required for the exit of PMPs from the ER together with 
SEC16B, a scaffold protein found in ER exit sites (Kim 2006; Sprangers & Rabouille 
2015).  
It is still controversially discussed whether these preperoxisomal vesicles derived from 
the ER develop into mature peroxisomes or if they serve to replenish preexisting perox-
isomes with PMPs and lipids.  
 
1.2.3 De novo synthesis 
In electron microscopy studies connections between peroxisomes and the endoplasmic 
reticulum (ER) were observed, providing first evidence for peroxisome de novo biogen-
esis from the ER (Novikoff et al. 1972). The reappearance of peroxisomes in peroxi-
some devoid cells upon the reintroduction of the necessary genes demonstrated the 
possibility of de novo peroxisome formation from the ER in yeast and human fibroblasts 
(Hoepfner et al. 2005; Toro et al. 2009). However, it is not unambiguously proven yet 
whether de novo synthesis takes place under normal physiological conditions, or if this 
is an artifact of peroxisome depleted cells.  
The role of the ER for peroxisome biogenesis has been studied in most detail in differ-
ent yeast strains. Van der Zand et al. presented a detailed model for de novo formation 
of peroxisomes in S.cerevisiae according to which PMPs are imported into the ER in a 
Sec61 translocon and a GET complex dependent manner, where they localize to spe-
cialized domains (Kim 2006; Schuldiner et al. 2008; Thoms et al. 2012; van der Zand et 
al. 2012). Interestingly different components of the peroxisomal matrix import machin-
ery localize to distinct ER subdomains. The docking complex (Pex13p, Pex14p), re-
sponsible for the first steps of protein import, and a RING finger complex (Pex2p, 
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Pex10p and Pex12p) are recruited to different peroxisomal ER (pER) sites (Lam et al. 
2011). Subsequently, pER regions containing PMPs bud off the ER in a Pex19p de-
pendent manner, thereby forming premature peroxisomes with different sets of PMPs 
and densities (Agrawal et al. 2011). Pex1p and Pex6p mediate a heterotypic fusion of 
the vesicles, which enables the assembly of functional protein translocon complexes 
facilitating the import of peroxisomal matrix proteins and finally the formation of mature 
peroxisomes (Titorenko et al. 2000).  
Less details are known about the de novo peroxisome biogenesis in mammals. In con-
trast to yeast only 13 peroxins necessary for peroxisome formation have been identi-
fied in mammals so far (Fujiki 2014). Mutations in three of these peroxins, Pex3, Pex16 
and Pex19 result in the absence of any peroxisomal structures (Hua & Kim 2015). 
PEX16 has been observed to co-translationally insert into the ER where it can facilitate 
PEX3 recruitment. PEX3 itself interacts with PEX19 to enable insertion of PMPs (Fang 
et al. 2004). In two laboratories assays were developed that allow to distinguish peroxi-
somes generated by growth and fission from peroxisomes formed by de novo synthesis 
via the presence or absence of fluorescent signals. Both groups observed an increase 
in the number of fluorescently tagged peroxisome formed by growth and division side 
by side with the reappearance of unlabeled peroxisomes. These observations though 
cannot prove the occurrence of de novo synthesis, as unlabeled peroxisomes can also 
arise by asymmetrical fission or subsequent fission events resulting in a dilution of the 
fluorescent signal (Kim 2006; Huybrechts et al. 2009). 
 
1.2.4 Growth and division 
Peroxisomal biogenesis by growth and division occurs via three main events: elonga-
tion, constriction, and finally fission. In mammalian cells the integral membrane protein 
PEX11β is a key player in these processes. PEX11β is a highly conserved protein, 
which interacts with membrane lipids and initiates the formation of membrane protru-
sions that elongate into tubular structures. PEX11β is found periodically distributed 
along elongated peroxisomes and presumably plays a role in membrane constriction 
(Delille et al. 2010; Koch & Brocard 2011). Moreover, it is involved in the recruitment of 
the adaptor proteins mitochondrial fission factor (MFF) and fission factor 1 (FIS1), 
which interact with the mechanochemical protein, dynamin related protein 1 (DRP1; 
Itoyama et al. 2013; Koch & Brocard 2011). Interestingly, mitochondria share all core 
components of organelle fission like MFF, FIS1, and DRP1, only PEX11β acts exclu-
sively on peroxisomes. DRP1 is mainly found in the cytoplasm and translocates as 
monomers to membranes, where it polymerases in a GTP hydrolysis dependent man-
ner. Subsequently GTP dependent constriction of the DRP1 ring results in membrane 
separation and formation of peroxisomes, which rejuvenate by import of newly formed 
peroxisomal matrix proteins. In mitochondria additional adaptor proteins have been 
described (MiD49 and 51), each of which can mediate DRP1 recruitment to the mito-
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chondrial membrane (Fujiki 2014). In contrast, in peroxisomes only combined overex-
pression of MFF and PEX11β results in fission (Itoyama et al. 2013). Recent experi-
ments indicate that PEX11β, apart from its dual role in membrane elongation and 
adapter protein recruitment, plays an additional role in the activation of DLP1 GTP hy-
drolysis activity driving membrane fission (Williams & van der Klei 2014).  
The existence of both biogenesis pathways is generally accepted, but their relative 
contribution and regulation remain enigmatic and may vary enormously in different or-
ganism and under different physiological conditions (Rachubinski 2014). In mammalian 
cells the majority of peroxisomes appears to arise via growth and fission under the ex-
perimental condition tested (Huybrechts et al. 2009; Delille et al. 2010). It remains to be 
determined whether ER derived preperoxisomal vesicles mainly deliver PMPs and li-
pids to preexisting peroxisomes or also contribute significantly to peroxisomal biogene-




Fig.  III: Schematic representation of peroxisome proliferation 
It is assumed that peroxisomes can arise via two distinct pathways. (1) De novo synthesis: preperoxisomal 
vesicles can bud of the ER and develop into mature peroxisomes by the import of matrix proteins and 
PMPs (left). (2) Growth and division: Mature peroxisomes elongate, constrict and divide resulting in the 
formation of multiple daughter peroxisomes (right). Proteins known to participate in peroxisomal fission are 
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1.3 Peroxisome dynamics  
1.3.1 Peroxisome Proliferation 
Peroxisomes are dynamic organelles whose abundance and protein composition is 
influenced by environmental and developmental signals. First evidence for the influ-
ence of exogenous stimuli on peroxisomes was published by Hess et al. in 1965 who 
observed peroxisome proliferation in rat liver cells in response to treatment with fibrates 
(Hess et al. 1965). Fibrates and other peroxisome proliferators were later shown to act 
via members of the steroid hormone receptor superfamily, which were subsequently 
termed peroxisome proliferator activated receptors (PPAR; Issemann & Green 1990). 
Upon ligand binding activated PPARs translocate to the nucleus where they heterodi-
merize with retinoid-X-receptors and bind to peroxisome proliferator response elements 
(PPRE) in the DNA to induce gene expression (Kliewer et al. 1992). PPREs consist of 
tandem repeats of the conserved consensus sequence AGGTCA localized in the pro-
moter region of target genes, such as enzymes of the peroxisomal β-oxidation (Lemay 
2006; Michalik et al. 2006). The three isoforms of PPARs are structurally homologous, 
but differ in their ligand binding domain and in tissue specific expression patterns (Is-
semann & Green 1990; Dreyer et al. 1992).  
In the rodent brain all PPAR isoforms are expressed during late embryonic develop-
ment. Whereas PPARα and PPARδ expression decreases postnatally, PPARβ expres-
sion remains abundant (O Braissant 2001). Little is known about PPARs in the human 
CNS, but in situ data indicates that all PPAR isoforms are present in the adult human 
brain (www.brain-map.org).  
Responses to PPARα treatment vary between species. Fibrate treatments in rodents 
can result in the formation of hepatic tumors, whereas in humans PPARα mediated 
effects are less pronounced (Peters et al. 2005). In the later PPARα appears to be 
mainly involved in inflammation, glucose homeostasis, and lipid regulation (Rakhs-
handehroo et al. 2010). Although PPARα is the most-studied PPAR so far, the mecha-
nism of peroxisome proliferation induction remains elusive. No regulatory effect of 
PPARα on Pex11β gene expression, which likely is a major player in peroxisome bio-
genesis, has been detected (Li et al. 2002). 
PPARβ and PPARγ appear to exert a major role in the brain, as several studies could 
show beneficial effects of PPARβ or PPARγ ligand treatment in neurodegenerative 
diseases (Heneka & Landreth 2007). Activation of PPARβ in oligodendrocyte precursor 
cells promotes differentiation and myelin maturation (Saluja et al. 2001). The CNS ex-
pression of Acyl-CoA synthase 2 (ACCA2), an enzyme of the peroxisomal β-oxidation, 
can be regulated by PPARβ, indicating a role in lipid homeostasis. Moreover, PPARβ 
null mutant mice exhibit altered myelination in the corpus callosum (Peters et al. 2000). 
PPARγ appears to exert a beneficial role in protection against brain inflammation and 
demyelination as PPARγ-deficient heterozygous mutant mice with induced experi-
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mental allergic encephalitis (EAE), a model for multiple sclerosis, show enhanced 
symptoms (Bright et al. 2003). Furthermore, treatment with the PPARγ agonist 
Pioglitazone improved the outcome of EAE induction in regard to inflammation and 
demyelination (Feinstein et al. 2002).  
Aside from PPARs, members of the PEX11 family seem to be involved in peroxisome 
proliferation. Mammalians contain three PEX11 variants: PEX11α, β, and γ, each of 
which is encoded by a single gene. Up-regulation of PEX11β results in peroxisomal 
elongation and subsequent fission, while depletion leads to increased peroxisomal siz-
es and strongly reduced peroxisomal numbers (Li & Gould 2002; Rottensteiner et al. 
2003). Pex11α is known to be induced via PPARα signaling, but has little effect on pe-
roxisome proliferation (McMullen et al. 2014). Light exposure can induce Pex11β ex-
pression in plants, but in mammals control of Pex11β expression remains enigmatic 
(Hu & Desai 2014). It has been shown that docosahexanoic acid (DHA; C22:6n), a 
product of peroxisomal β-oxidation, induces peroxisome proliferation in fibroblast from 
patients with impaired β-oxidation, in a PEX11β dependent manner (Itoyama et al. 
2012).  
 
1.3.2 Degradation of peroxisomes  
In mammals three independent systems for degradation of peroxisomes have been 
identified. 15-Lipoxygenase is a cytosolic enzyme that associates to the peroxisomal 
membrane and mediates membrane perforation. The peroxisomal matrix is thus ex-
posed to cytosolic proteases, which results in rapid protein degradation (Yokota 2003). 
LON proteases are serine peptidases, which recognize and degrade misfolded pro-
teins. The peroxisome specific LON protease has been described to degrade proteins 
in the peroxisomal lumen and might not only be responsible for a reduction of peroxi-
somal mass, but also for peroxisomal protein quality control (Kikuchi et al. 2004). The-
se two pathways account for about 20-30% of peroxisomal degradation. The majority of 
peroxisomes is degraded via autophagic mechanisms, termed pexophagy, which was 
shown in autophagy impaired Atg7-/- mice (Iwata et al. 2006). Selective binding of 
adapter molecules to the peroxisomal surface and LC3 protein mediate the engulfment 
of peroxisomes by autophagosomes, which subsequently fuse with lysosomes. Peroxi-
somal membranes and proteins are subsequently degraded by lysosomal hydrolases 
(Suzuki & Ohsumi 2007).  
How peroxisomal degradation is regulated in not well known yet. Ubiquitination is a 
common recognition signal for selective autophagy (Shaid et al. 2012). Ectopic expres-
sion of ubiquitinylated PMPs triggered peroxisomal degradation via the adaptor pro-
teins p62 and NBR1 revealing a role for ubiquitin (Ub) also for pexophagy (Kim et al. 
2008). However, which proteins serve as physiological targets for ubiquitination and 
associated regulatory mechanism remain elusive. Recently, two studies revealed a 
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ROS induced ATM kinase dependent phosphorylation of PEX5, which lead to mono-
ubiquitination of peroxisome localized PEX5. Ub-PEX5 is subsequently recognized by 
an adaptor protein, which mediates autophagosome engulfment. ATM kinase is known 
as a DNA-damage sensor, but was recently found to also reside on the cytoplasmic 
side of the peroxisomal membrane, a strategic localization for sensing peroxisomal 
derived ROS. Apart from its role in selective autophagy ATM has been found to en-
hance the autophagic flux via TSC2 activation, which itself inhibits mTORC1 signaling 
and thus stimulates autophagy (Nordgren et al. 2015; Zhang et al. 2015). Lately also 
TSC1 and 2 have been detected on the peroxisomal membrane (Zhang et al. 2013).  
Peroxisomal degradation can be induced by treatment and subsequent removal of pro-
liferating agents (Iwata et al. 2006). Furthermore starvation conditions have been 
shown to result in pexophagy involving PEX14 LC3 interaction (Hara-Kuge & Fujiki 
2008).  
 
1.4 Central nervous system glial cells  
Glial cells account for about 90% of all brain cells in humans, whereas neurons make 
up the residual 10%. Similarly, in rodents the percentage of glial cells (65%) outnum-
bers neurons (35%; Baumann & Pham-Dinh 2001). Central nervous system (CNS) glia 
comprise astrocytes, microglia and oligodendrocytes, which participate i.a. in the 
trophic support of neurons and regulation of extracellular ion- and transmitter concen-
trations. Furthermore, they enable enhanced nerve conduction velocity and mediate 
the immune response.  
The name astrocyte derives from the star-shaped morphology of the cells. Astrocytic 
endfeet interact with endothelial blood capillary cells thereby contributing to the for-
mation of the blood-brain barrier, which tightly controls the entry of substances from the 
blood (Ballabh et al. 2004). Astrocytes are in close contact to synapses where they not 
only control the ion homeostasis in the extrasynaptic space, but as well provide meta-
bolic support for neurons and even play a role in synaptic plasticity (Mauch et al. 2001; 
Pellerin et al. 2007; Suzuki et al. 2012; Saab et al. 2013). Astroglia are activated in 
response to brain insults like injury, infection and neurodegenerative diseases. Such a 
reactive gliosis is associated with morphological changes and differential regulation of 
certain genes e.g. the upregulation of glial fibrillary acidic protein (GFAP; Pekny & Pe-
kna 2004).  
Microglia are the immune cells of the brain. These are monocyte derived cells like their 
peripheral counterpart, the macrophages. For a long time they were considered as 
resting cells when not activated, but as the microglial processes were observed to con-
stantly move, it is now believed that in the healthy brain these cells actively and contin-
uously scan the brain parenchyma (Nimmerjahn et al. 2005). When activated they re-
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organize, become motile and migrate towards the site of injury. Furthermore, they can 
release cytotoxic substances and clear pathogens or apoptotic cells by phagocytosis 
(Bechmann & Nitsch 1997; Brown & Neher 2014). This goes along with a shortening 
and thickening of the long, branched processed and an increased expression of sever-
al genes such as the cytosolic ionized calcium-binding adapter molecule 1 (IBA1) and 
surface antigens, such as MAC-3 (Ito et al. 1998). Transient microglial activation ap-
pears to be beneficial whereas prolonged periods of reactive microgliosis have detri-
mental effects (Hanisch & Kettenmann 2007). In the CNS, oligodendrocytes enwrap 
axons with multiple membranes to form myelin, a lipid rich insulation that enables rapid 
action potential propagation. Moreover, myelin may provide routes for oligodendro-
cytes-derived metabolites to trophically support the axonal energy metabolism (Griffiths 
et al. 1998; Kassmann et al. 2007). Myelination starts prenatally in humans and mice 
and likely continues throughout life (Young et al. 2014). During embryogenesis oli-
godendrocyte progenitor cells derive from the neuroepithelium of the ventral neural 
tube. The majority of these progenitor cells proliferate and mature to myelinating oli-
godendrocytes (Doetsch et al. 1997). A subpopulation of progenitors, referred to as 
oligodendrocyte precursor cells (OPC), does not differentiate and remains in a prolifer-
ative state. OPCs have a homogeneous distribution throughout the brain parenchyma 
and are oligodendrocyte lineage restricted. They can develop into mature oligodendro-
cytes and aid remyelination during brain insults (de Castro 2013).  
Oligodendrocytes enwrap up to 20 to 60 individual axon segments with their processes, 
which broaden at the contact sides and form myelin stacks (internodes) with up to 100 
membrane layers. Internodes are regularly interspersed by short unmyelinated regions, 
the Nodes of Ranvier, which enable electric impulse propagation via voltage-gated so-
dium channels (Matthews & Duncan 1971; Simons & Nave 2016). Myelin is composed 
of compacted membranes and only the inner and the outer tongue, myelinic channels 
and paranodal loops, encompassing the Nodes of Ranvier, contain cytoplasm. Com-
pared to other biological membranes myelin contains higher amounts of lipids, which 
make up 70 to 85% of the dry mass. They mainly comprise phospholipids (43%), glyco-
lipids (32%) and cholesterol (27%; Evans & Finean 1965; Stoffel & Bosio 1997). The 
lipid rich composition results in a high electrical resistance of myelin, which lowers the 
axonal capacitance. Myelin lipid composition differs from other membranes. Although 
there are no unique myelin lipids, cerebosides are much more abundant in myelin than 
in other biological membranes. Moreover, white matter lipids contain higher levels of 
saturated long-chain fatty acids (O'Brien & Sampson 1965). The high percentage of 
lipids in myelin membranes goes along with a reduced variety of myelin proteins. The 
proteolipid protein (PLP) and the myelin basic protein (MBP) together make up about 
80% of the protein mass (Boiko & Winckler 2006). Both proteins are integral membrane 
proteins. 2`3`-Cyclic nucleotide-3`-phosphodiesterase (CNP) is found in cytoplasmic 
regions. CNP is an early marker for oligodendrocytes as it is already expressed in early 
stages of oligodendrocyte differentiation (Scherer et al. 1994).  
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For experimental purposes OPCs can be derived from newborn mice and cultured on 
astrocytes in a fetal bovine containing serum that drives OPC proliferation. OPC are 
subsequently separated and cultured in a medium allowing OPC differentiation into 
mature non-myelinating OL that form myelin-like membrane sheets (McCarthy & de 
Vellis 1980).  
 
1.5 Peroxisomal disorders  
Peroxisomal disorders can be separated into two groups. I) Peroxisomal biogenesis 
disorders (PBDs), which are caused by mutations in peroxins essential for peroxisome 
formation and II) single peroxisome transporter or enzyme deficiencies (PTEDs). X-
linked adrenoleukodystrophy (X-ALD), a PTED, shows the highest incidence among 
peroxisomal diseases, with about 1:17,000 newborn boys affected. Taken together 
peroxisomal disorders have an expected incidence of about 1:5,000 individuals ac-
counting for a substantial fraction of inborn metabolic diseases (Waterham et al. 2016).  
 
1.5.1 Peroxisomal biogenesis disorders  
Human peroxisomal biogenesis disorders are autosomal recessive diseases caused by 
mutations in one of 13 peroxins essential for peroxisome biogenesis and membrane or 
matrix protein import (Gould & Valle 2000). These mutations result either in a general-
ized loss of peroxisomal function (peroxisomal ghosts) or in the case of Pex3, Pex16 
and Pex19 mutations in the absence of peroxisomal structures (Matsuzono et al. 1999; 
Sacksteder et al. 2000). PBDs are subdivided into Zellweger syndrome spectrum (ZSS) 
disorders and rhizomelic chondrodysplasia punctata type 1 (RCDP). The latter is 
caused by mutations of Pex7, the cytosolic receptor for peroxisomal proteins, contain-
ing a PTS2, which comprise enzymes involved in plasmalogen synthesis and phytanic 
acid degradation, resulting in deficiency and accumulation of these metabolites respec-
tively (Jansen et al. 2004; Wierzbicki 2007). The clinical phenotype of RCDP1 patients 
is less severe than in ZSS patients (Rosewich 2005; Trompier et al. 2013).  
ZSS disorders are further differentiated into a severe manifestation, the Zellweger syn-
drome (ZS), an intermediate form, the neonatal adrenoleukodystrophy (NALD) and the 
least severe presentation, the infantile Refsum disease (IRD). ZSS disorders range 
from multisystemic disorders resulting in death within the first year of life (ZS) to devel-
opmental defects with a higher probability to survive into adolescence or adulthood 
(NALD and IRD). All encompass malformations of cortex and cerebellum, peripheral 
neuropathy and inflammatory demyelination (Waterham et al. 2016).  
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1.5.2 Single peroxisome transporter and enzyme deficiencies  
Single peroxisome transporter or enzyme deficiency (PTED) mostly comprise defects 
in enzymes involved in peroxisomal α- or β-oxidation or ether lipid synthesis, as well as 
peroxisomal membrane transporters mediating metabolite transport across the peroxi-
somal membrane.  
Phytanoyl-CoA 2-hydroxylase (PHYH) participates in peroxisomal α-oxidation. Muta-
tions in PHYH result mainly in the accumulation of phytanic acid, which causes a slowly 
progressive phenotype starting in late childhood, called Refsum disease (Jansen et al. 
2004). Apart from α and β-oxidation peroxisomes play an important role in ether lipid 
synthesis as they harbor three enzymes necessary for plasmalogen synthesis. Muta-
tions in any of these enzymes result in rhizomelic chondrodysplasia punctata type 2, 3 
and 4 (RCDP2-4), which usually exhibit milder pathology than RCDP1 (Ofman et al. 
1998; Itzkovitz et al. 2011).  
The most common PTED, X-adrenoleukodystrophy, is caused by mutations in the 
ABCD1 gene, which encodes for a peroxisomal membrane protein. ABCD1 mediates 
import of straight chain very long chain fatty acids (VLCFA) into peroxisomes, which 
are further degraded by peroxisomal β-oxidation (Tanaka et al. 2002; Wiesinger et al. 
2013). In patients VLCFA accumulate in cells and plasma. The pathology is extremely 
variable even within families, but two distinct clinical manifestation can be defined. I) 
Severe cerebral ALD (CALD) involves cerebral demyelination, neurological deteriora-
tion, and premature death. It often already develops in infancy (3-10 years) and is then 
termed childhood CALD (CCALD). Inflammation is a prominent feature of CALD includ-
ing reactive gliosis as well as macrophage and lymphocyte infiltration (Moser et al. 
1992; Powers et al. 1992; Eichler et al. 2008). II) Adrenomyeloneuropathy (AMN) on 
the contrary is a slow progressive variant with an onset in the second to third decade of 
life. It primarily affects the peripheral nervous system and 2/3 of the patients develop 
adrenocortical insufficiency (Moser et al. 1992). The factors determining the severity of 
the disease remain elusive.  
Patients with peroxisomal β-oxidation defects are most severely affected among the 
PTEDs, and show a pathology comparable to ZSS patients. They comprise mutations 
in Acyl-CoA oxidase 1 (ACOX1), multifunctional protein 2 (MFP2) and acetyl-
Coenzyme A acyltransferase1 (ACAA1). Whereas ACOX1 is solely involved in the β-
oxidation of straight chain VLCFA, MFP2 catalyzes the second and third step in the β-
oxidation of both straight chain VLCFA and branched-chain FA. Accordingly ACOX1-
deficient patients only exhibit elevated levels of VLCFAs, whereas DBP-deficient pa-
tients show increased levels of VLCFA, pristanic acid and bile acid intermediates (Poll-
The et al. 1988; Ferdinandusse et al. 2005). The clinical presentation of 
ACOX1-deficient patients is, as observed in X-ALD, very variable. Although the number 
of described patients is limited, early fatal to mild late-onset phenotypes have been 
reported (Ferdinandusse et al. 2007). Most MFP2-deficient patients exhibit a severe 
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pathology resembling the Zellweger syndrome spectrum, including brain malformation 
and psychomotor retardation. However, whole exome sequencing identified 
MFP2-deficient patients with milder presentations surviving into adulthood (Ferdinan-
dusse et al. 2006; Lieber et al. 2014; Lines et al. 2014). Leukodystrophy, the degenera-
tion of brain white matter, is a common pathological hallmark of the ZSS and most dis-
eases caused by dysfunctional enzymes of the peroxisomal β-oxidation and as well by 
ABCD1-deficiency.  
Peroxisomal β-oxidation defects and PBDs appear to represent a continuum of pheno-
types, which cannot clearly be distinguished by only the biochemical or clinical repre-
sentation. The historical naming stresses the phenotypic similarities between different 
peroxisomal diseases. In reference to X-ALD certain clinical phenotypes of the Zellwe-
ger syndrome spectrum are referred to as neonatal ALD while ACOX1-deficiency is 
called pseudoneonatal ALD. The link between biochemical alterations and neuro-
degeneration in peroxisomal β-oxidation defects remains unresolved, but the overlap-
ping phenotypes may indicate a common pathomechanism of PBDs and peroxisomal 
β-oxidation defects including X-ALD. The severity of the phenotype in peroxisomal β-
oxidation impairment suggests that dysfunction of the peroxisome β-oxidation is mainly 
responsible for disease etiology. It could also be envisioned that impaired β-oxidation 
might cause the loss of additional peroxisomal functions and explain the similarity be-
tween single enzyme defects and peroxisomal biogenesis defects.  
 
1.5.3 Mouse models of peroxisomal diseases 
The Abcd1 null mouse mutant was the first peroxisomal disease model. It was gener-
ated in three independent laboratories in 1997 as a model for X-ALD (Kobayashi 1997; 
Lu et al. 1997; Forss-Petter et al. 1997). Since then a variety of conventional and con-
ditional mouse mutants have been developed to investigate the pathomechanism of 
peroxisomal diseases. ABCD1-deficient mice exhibit elevated levels of VLCFA, but fail 
to develop cerebral neurodegeneration. Instead, a late onset myeloneuropathy is ob-
served similar to AMN patients (Pujol et al. 2002).  
PEX5 is the import receptor for most peroxisomal proteins. In its absence peroxisomal 
structures are formed, which are almost devoid of enzymatic activity (Lazarow & Fujiki 
1985, Yamasaki et al. 1999). Interestingly, CnpCre/Wt*Pex5-/- conditional knock-out mice 
lacking peroxisomal function in oligodendrocytes display inflammatory subcortical de-
myelination, axonal degeneration and other hallmarks of CALD starting around 
4 months of age (Kassmann et al. 2007). These observations suggest that in CALD 
patients, defects beyond ABCD1-dysfunction might cause demyelination. As demye-
linating lesions start in densely myelinated areas of the brain an activity or energy de-
pendent mechanism might be envisioned for the development of secondary peroxiso-
mal defects.  
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The ablation of either Acox1 or Scpx both show rather mild phenotypes in mice and fail 
to develop cerebral demyelination. MFP2 is a bifunctional enzyme, which catalyzes two 
central steps in the peroxisomal β-oxidation. Its absence in man results in a severe 
ZSS like phenotype. MFP2-deficient mice are indistinguishable from their wildtype lit-
termates at birth but subsequently fail to thrive. One third die within the first three 
weeks whereas the surviving mice develop progressive motor deficits and die around 
six month of age. Similar to MFP2-deficiency in humans, mice show elevated levels of 
VLCFA and impaired bile acid synthesis, but unlike patients they do not exhibit neuro-
developmental defects or cerebral inflammatory demyelination. Instead white matter 
tracts are spared of reactive gliosis, which is mainly located in grey matter (Baes 2000; 
Huyghe et al. 2006). To enable the investigation of the consequences of peroxisomal 
β-oxidation impairment on demyelination the oligodendrocyte specific 
CnpCre/Wt*Mfp2-/- conditional knock-out was developed and studied up to the age of 12 
month (Verheijden et al. 2013). Interestingly, mice remained clinically inconspicuous 







                                                                                                    AIMS OF THE STUDY 
 
 19 
2 Aims of the study 
Mice lacking peroxisomal function in oligodendrocytes (CnpCre/Wt*Pex5-/-) exhibit reac-
tive gliosis, inflammation, and symmetrical demyelination in the corpus callosum, a 
major white matter tract of the CNS (Kassmann et al. 2007). This pathology is reminis-
cent of human peroxisomal diseases that are caused by single mutations in enzymes 
or transporters involved in peroxisomal β-oxidation, such as MFP2, ACOX1, and 
ABCD1. The phenomenon of a similar pathology by naturally occurring peroxisomal 
enzyme defects on the one side, and by the experimental approach to cell type-
specifically ablation of the complete organelle function on the other side, may be ex-
plained by a two-step disease mechanism. Impaired peroxisomal β-oxidation possibly 
induces a chemical imbalance inside the organelles, especially in cells of metabolically 
challenged tissue, e.g. in oligodendrocytes of lipid-rich myelin. A perturbed intra-
organelle equilibrium may then result in secondary defects and a broad dysfunction of 
peroxisomes. According to this hypothesis, the rate of peroxisomal turnover may be 
one important factor to influence such accumulation of defects. A second important 
factor may be the mode of peroxisomal proliferation, which is in principal possible by 
both, de novo synthesis from the ER and fission of preexisting peroxisomes. 
The aim of this work was to investigate mouse models with impaired peroxisomal β-
oxidation regarding a late-onset cerebral pathology and possible secondary defects in 
oligodendroglial peroxisomes. To this end first, novel transgenic animals expressing 
the photoconvertible fluorescent protein mEos2 fused to a peroxisomal targeting se-
quence (PTS) under control of the oligodendrocyte-specific Cnp-promoter 
(Cnp-mEos2-PTS1) should be generated. Secondly, a mouse model with cell type-
specific ablation of the essential peroxisomal β-oxidation enzyme, multifunctional pro-
tein 2 (MFP2), were to analyze regarding late-onset white matter defects. And thirdly, 
the conditional MFP2-deficient mice and conventional ABCD1 knockout mice, that only 
lack peroxisomal β-oxidation of very long chain fatty acids, shall be intercrossed to 
CNP-mEos2-PTS mice. These double transgenic animals shall facilitate the analysis of 
oligodendroglial peroxisomes in mouse models with defects in peroxisomal β-oxidation 
in vivo and in vitro. Therefore, an in vitro assay was established that allows to study 
peroxisomal degradation as well as peroxisomal biogenesis. 




3.1 Analysis of aged CnpCre/Wt*Mfp2-/- mutant mice  
Mice lacking complete peroxisome function in myelinating glial cells (CnpCre/Wt*Pex5-/- 
cKO) exhibit symmetrical subcortical demyelination, reactive gliosis and inflammation 
that is reminiscent of human leukodystrophy patients with a defect only in peroxisomal 
β-oxidation. This similarity may be explained by a secondary loss of peroxisome func-
tion in patients due to impaired peroxisomal β-oxidation. To investigate a possible 
gradual loss of peroxisome function a suitable mouse model was to be developed. The 
multifunctional protein 2 (MFP2) was a potential candidate as it participates essentially 
in peroxisomal β-oxidation. To circumvent developmental effects of MFP2-deficiency 
and to concentrate on white matter, an oligodendrocyte specific MFP2-conditional mu-
tant mouse (CnpCre/Wt*Mfp2-/-) was generated. Up to 12 months of age mice were phe-
notypically inconspicuous, which is not unexpected since diseases caused by peroxi-
somal enzyme defects often display an age related onset (Verheijden et al. 2013). We 
investigate the long term effects of impaired peroxisomal β-oxidation on peroxisome 
function in metabolically challenged tissue in aged CnpCre/Wt*Mfp2-/- mutants (≥ 16 
months) and focused on the corpus callosum (CC), the brains largest myelinated struc-
ture, which is strongly affected in different peroxisomal diseases (Kassmann et al. 
2007; van der Knaap et al. 2012).  
 
3.1.1 Subcortical demyelination  
Progressive symmetrical demyelination of the corpus callosum is a hallmark of several 
peroxisomal diseases. Mice lacking functional peroxisomes from myelinating oligoden-
drocytes exhibited a pathology comparable to human patients, as shown by immuno-
histochemical stainings for myelin proteins and myelin specific dyes (Kassmann et al. 
2007). To study white matter integrity in the brain of aged (≥ 16 months) CnpCre/Wt*Mfp2-
/- (hereafter termed mutants) and Mfp2flox/flox mice (hereafter referred to as CTR) the 
myelin specific Gallyas impregnation and Luxol fast blue staining for myelin lipoproteins 
were conducted. Focal demyelination was observed in the Genu, the anterior end of 
the corpus callosum (Fig. 1A; B), but was less obvious in other myelin structures (not 
shown). Electron microscopy was conducted in collaboration with Dr. Wiebke Möbius 
and confirmed the decrease of myelin in the anterior Corpus callosum (Fig. 1C).  
Disease progression in patients with peroxisomal β-oxidation defects is monitored by 
regular magnetic resonance tomography (MRI) measures. In T2 weighted magnetic 
resonance images demyelination was revealed by the change from hypointense (dark) 
to hyperintense (bright) signals in lipid rich tissue. In both patients and conditional 
Pex5-/- mice symmetrical subcortical loss of myelin can be observed by MRI (Kass-
mann et al. 2011). To investigate the onset of demyelination, CnpCre/Wt*Mfp2-/- mice 
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underwent magnetic resonance imaging in collaboration with T. Michaelis (Biomedical 
NMR, Göttingen) at 2, 6, 14 and 19 months. No alteration in myelin compartments 
could be observed, indicating a more subtle demyelination compared to patients and 
conditional CnpCre/Wt*Pex5-/- mice (Fig. 1D). Although demyelination was undetectable 
in MRI the histological findings proved a late onset demyelination in mutants that re-
sembles human peroxisome β-oxidation defects.  
           
 
Fig. 1: Subcortical demyelination in CnpCre/Wt*Mfp2-/- mice 
(A) Overview of wax embedded CTR (Mfp2flox/flox) and mutant brains; anterior CC highlighted by white box. 
Scale bar: 1000 µm. (B) Myelin stainings of sagittal wax sections from ≥ 16months-old control and mutant 
mice. Luxol Fast Blue together with Haematoxilin-Eosin staining (top) and Gallyas silver impregnation 
(bottom) reveal demyelination of the anterior CC in conditional mutant mice. Images show the Genu of CC 
and a magnification. Scale bar: 200 µm; magnified image: 50 µm. (C) Electron micrographs of the anterior 
corpus callosum confirm demyelination in CnpCre/Wt*Mfp2-/- mice. Scale Bar: 500 nm (D) T2 weighted mag-
netic resonance images of control and mutant mice at different ages do not show subcortical demye-
lination.  
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Histological alterations were accompanied by altered cage behavior of CnpCre/Wt*Mfp2-/- 
mice, which were readily distinguishable from CTR littermates at ≥ 16 months. The grid 
test showed increased numbers of forelimb and hindlimb slips for most mutant animals 
indicating ataxia (Fig. 2A). Using the elevated beam test, differences were even more 
prominent. While control mice reached the hiding box failing once at maximum, mutant 
mice had difficulties to accomplish the task (Fig. 2B). One mutant animal was even 
excluded from the tests due to complete hindlimb paralysis. Furthermore the mice were 
scored regarding presence (+) or absence (-) of altered fur appearance, kyphosis, gait 
abnormalities, tremor, passiveness and hindlimb paralysis. Control mice showed a 
score distribution between 0 and 2, mutant mice between 3 and 6. Additionally, body-
weight of mutants was gaining less starting from approximately 11 month of age. Due 
to mouse-keeping problems the number of animals tested so far is too low to allow sta-
tistical analysis. However, the motor impairment of mutants at higher age was apparent 
and consistent with observations of the same mutants made in another laboratory (M 





















    
 
Fig. 2: Clinical symptoms and sings for ataxia in ≥ 16-month-old CnpCre/Wt*Mfp2-/- mutants  
(A) The grid test showed increased numbers of forelimb and hindlimb slips for most mutant animals when 
covering a distance of 80 cm. (B) In the elevated beam test mutant mice had difficulties to accomplish the 
task, whereas control mice reached the hiding box with no more than one slip. (C) The evaluation of sev-
eral clinical symptoms comprised in a final clinical score showed higher values for CnpCre/Wt*Mfp2-/- mu-
tants than for CTRs at ≥ 16 months. (D) CnpCre/Wt*Mfp2-/- mutants exhibited a tendency to less weight gain 
starting at around 12 months. (CTR n = 8, mutant n ≥ 3; Mean + SD). 
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3.1.2 Axonal swellings and neuronal loss  
Myelin is not only important for saltatory impulse propagation, but also for axonal sup-
port. Demyelination may therefore result in axonal swellings and neuronal loss (Kass-
mann et al. 2007). Bielschowsky silver impregnation on sagittal sections of wax em-
bedded brains of ≥ 16-months-old CnpCre/Wt*Mfp2-/- and CTR mice allowed the 
visualization of neurons and axons (Fig. 3A). Similar to demyelination, axonal loss was 
detectable in the Genu of CC (Fig. 3A).  
The amyloid precursor protein (β-APP) is transported anterogradely in axons and its 
accumulation indicates axonal swellings, which precede axonal degeneration. Im-
munohistological stainings showed β-APP accumulation in the anterior corpus callosum 
of all ≥ 16-month-old CnpCre/Wt*Mfp2-/- mice analyzed (Fig. 3B). Such APP spheroids 
were barely detectable in CTR brains. Manual quantification in Fiji showed high varia-
tion between animals, which appeared to correlate with disease severity (data not 
shown).   
 
       
Fig. 3: Axonal loss and signs for neuronal degeneration in CnpCre/Wt*Mfp2-/- mice 
(A) Bielschowsky silver impregnation visualizes neurons and axons on sagittal sections of wax embedded 
brains from ≥ 16-month-old control and CnpCre/Wt*Mfp2-/- mice and indicates axonal loss in the anterior CC 
in mutants. (B) β-APP spheroids (arrows) can be observed by immunohistological stainings on wax em-
bedded brains of ≥ 16-month-old animals. Quantification reveals a significant increase of β-APP spheroids 
in mutant mice (CTR n = 5, mutant n = 7; Mean + SD). Scale bar: 200 µm; magnified image: 50 µm.  
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3.1.3 Reactive gliosis in the frontal corpus callosum  
CNS damage can elicit responses like proliferation, hypertrophy and altered gene ex-
pression patterns in microglia, astrocytes and oligodendrocytes. Together, these pro-
cesses are referred to as reactive gliosis and can be both beneficial or detrimental for 
the CNS. During reactive gliosis activated microglia migrate to the site of injury. Their 
activation results in an increased expression of the cytosolic ionized calcium-binding 
adapter molecule 1 (IBA1) and of surface antigens such as MAC-3, which are unde-
tectable in quiescent microglia. Astrocytes respond by proliferation accompanied by 
upregulation of glial fibrillary acidic protein (GFAP). Since reactive gliosis is a feature of 
peroxisomal defects in humans and in the PEX5-conditional mouse mutant, IBA1, 
MAC-3, and GFAP immunohistological stainings were carried out. Vibratome sections 
were investigated for IBA1 signal; paraffin embedded sections were stained for MAC-3. 
Both proteins indicated strong accumulation of microglial cells in the Genu of corpus 
callosum of aged (≥ 16 months) mutant mice (Fig. 4 A and B). Immune mediated detec-
tion of GFAP on vibratome sections revealed an increase in expression and number of 
astrocytes (Fig. 4C). Reactive gliosis seemed most prominent in areas affected by de-
myelination and axonal degradation.  
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Fig. 4: ≥ 16-month-old CnpCre/Wt*Mfp2-/- mice exhibit reactive gliosis in the frontal CC  
(A) IBA1 antibody staining on vibratome sections visualizes the gradual distribution of microglia along the 
CC (encompassed by dashed line). Microglial density is highest in the Genu. (B) IBA1 immunohistological 
staining and quantification prove a significant increase of the IBA1 positive area in mutants compared to 
CTRs. The microglial surface marker protein MAC-3 is rarely detectable in CTR mice. It is strongly in-
creased in CnpCre/Wt*Mfp2-/- mice, confirming the activated state of microglia. (C) Astrocyte number and 
GFAP expression are increased in mutants as shown by a immunohistochemical staining against GFAP 
and quantification of GFAP positive area. (CTR n ≥ 3, mutant n ≥ 4; Mean + SD). Scale bar: 200 µm; mag-
nified image: 100 µm.  




3.1.4 T-lymphocyte infiltration in sites of demyelination 
The blood-brain barrier separates the circulating blood from the cerebrospinal fluid im-
peding the entry of peripheral immune cells. This so-called immune privilege of the 
brain is affected by certain inflammatory diseases of the central nervous system. In 
Multiple Sclerosis and in X-linked Adrenoleukodystrophy T-lymphocytes are found in 
sites of demyelination in the brain. To investigate the presence of T-lymphocytes in our 
mouse model an antibody staining against the T-lymphocyte co-receptor CD3 was per-
formed on wax embedded tissue of ≥ 16-month-old mice. CD3 positive cells were pre-
sent in all CnpCre/Wt*Mfp2 conditional mutant mice analyzed and were mainly found in 
the anterior CC (Fig. 5).  
             
 
Fig. 5: T-lymphocyte infiltration in the anterior CC in CnpCre/Wt*Mfp2-/- mice 
Immunohistochemical detection of CD3 shows an increase of T-lymphocytes in wax embedded samples 
from ≥ 16-month-old CnpCre/Wt*Mfp2-/- mice compared to CTR mice. (CTR n = 5, mutant n = 7; Mean + SD). 
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3.2 Generation and analysis of Cnp-mEos2-SKL transgenic 
mice 
The high abundance of peroxisomes in CNS cells renders subcellular analysis by tradi-
tional immunohistochemical co-labeling techniques difficult. To allow analysis of perox-
isomes specifically in myelin-forming glial cells we generated mice expressing a fluo-
rescent protein with a peroxisomal targeting sequence (PTS) under the control oft the 
oligodendrocyte specific CNP promoter. Employing a photoconvertible fluorescent pro-
tein such as mEos2 significantly broadens the spectrum of applications (McKinney et 
al. 2009). Apart from facilitating the subcellular investigation of peroxisomes it as well 
enables a pulse-label approach of peroxisomal subpopulations. Data of the following 
chapter has been published (Richert et al. 2014).  
 
3.2.1 Generation of Cnp-mEos2-PTS1 transgenic mice 
For the analysis of peroxisomes in myelinating glial cells we chose to express the pho-
toconvertible fluorescent protein mEos2 under control of the myelin specific 2´3´cyclic 
nucleotide phosphodiesterase (Cnp) promoter. The mEos2 coding sequence was am-
plified by PCR using an antisense primer, which contained a 9 bp sequence encoding 
Ser, Lys, Leu, the signal for peroxisomal targeting (PTS1) followed by a stop codon 
and a restriction site sequence. After restriction digest the 1.1 kb fragment was ligated 
into the Cnp1 plasmid, which had been depleted of 57 bp upstream of the start codon 
responsible for mitochondrial targeting in the CNP2 isoform. Following linearization the 
fragment flanked by a SV40 PolyA sequence on the 3´end (Fig. 6A) was injected into 
fertilized C57BL/6N oocytes, from which five potential founders were identified by rou-
tine genotyping PCR. The genotyping primers were designed such that a 720 bp frag-
ment was yielded from transgenic, but not CTR animals (Fig. 6B). The offspring of two 
founders was expanded into separate mouse lines and further analyzed. Mice were 
born at the expected Mendelian frequency and were indistinguishable from wildtype 
litter mates.  
                                 
Fig. 6: Structure of the Cnp-mEos2-PTS1 transgene 
(A) The 5.1 kb Cnp-mEos2-PTS1 transgene consists of the Cnp1 promoter encompassing Exon 0 (E 0) 
followed by the mEos2 coding sequence with a 3´terminal PTS1 sequence flanked by a SV40 polyad-
enylation signal. (B) PCR with genotyping primers yields a 720 bp band in the presence of the transgene. 
No band is detectable in WT.  
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3.2.2 Spatio-temporal expression pattern of Cnp-mEos2-PTS1 
The promoter and the site of integration into the DNA are crucial for transgene expres-
sion regarding tissue specificity and expression level. Although the CNP expression 
pattern is well characterized, the method applied for transgenic mouse generation al-
lowed random integration of exogenous DNA into chromosomes, making further char-
acterization of founder mice necessary.  
Of five founders obtained from oocyte injection two were selected and the offspring 
expanded for further analysis. In this work I will concentrate on the results from one 
mouse line best suited for peroxisomal analysis in the brain due to relatively even 
transgene expression throughout the white matter structures of the CNS and appropri-
ate expression levels. Onset and distribution of Cnp-mEos2-PTS1 expression were 
investigated by wide-field microscopy on vibratome section of transgenic mice at differ-
ent ages. The punctate pattern of mEos2-PTS1 fluorescence was already detectable in 
the cerebellum at postnatal day 1 (P1) in line with the developmental expression of 
CNP starting around embryonic day 13 (Data not shown; Gravel et al. 1998). At P7 
fluorescence was observed in the brain stem and spinal cord. Only later also the frontal 
brain areas were mEos2 positive. At P14 white matter structures such as the corpus 
callosum, the anterior commissure, and the cerebellar white matter were distinguisha-
ble from grey matter by pronounced transgene expression (data not shown). mEos2 
expression was visualized in all areas of the CNS with a gradient of stronger expres-
sion in the caudal as compared to the rostral region. In mature animals the expression 
pattern was essentially the same, but fluorescence intensity of the mEos2 signal in-
creased, indicating higher levels of transgene expression (Fig. 7A, B; data not shown). 
mEos2 expression was absent from most other tissues tested including heart, kidney, 
liver, lung and muscle. However, Schwann cells, the myelin forming cells in the periph-
eral nervous system, exhibited extremely low levels of mEos2 signal as seen on teased 
fiber preparations of sciatic nerves (data not shown), which is in line with published 
data of low CNP expression in these cells (Sprinkle et al. 1985). Consistent with pub-
lished data on Cnp-promoter activity mEos2 expression was also found in cells of testis 
and spleen (Fig. 7C; Weissbarth et al. 1981; Davidoff, Middendorff, Köfüncü, Müller, 
Ježek, & Holstein 2002a).  




Fig. 7: Expression of mEos2 in the CNS of Cnp-mEos2-PTS1 transgenic mice 
(A) Sagittal brain vibratome sections of two-month-old transgenic mice reveal pronounced transgene ex-
pression in white matter tracts. Scale bar: 1.5 mm. Middle and bottom panels show magnifications of the 
corpus callosum (CC), the anterior commissure (AC), the cerebellar white matter (CB) and the cerebral 
cortex (CTX). Scale bar: 20 µm. (B) Fluorescence microscopy shows even and abundant distribution of 
transgene expression in spinal cord cross sections (left; Scale bar 500 µm). Magnification of the spinal 
cord white matter shows punctate distribution of the fluorescent signal (WM; right; Scale bar: 20 µm). (C) 
Punctate pattern of mEos2 fluorescence in spleen and testis of 2 and 6-month-old transgenic mice shows 
transgene expression in cell types of both organs and indicates peroxisomal localization. Scale bar: 10 µm 
 
mEos2 showed a punctate subcellular pattern indicating organelle targeting of the 
transgene. The majority of puncta was accumulated perinuclearly. Cells featuring peri-
nuclear mEos2 signal were identified as oligodendrocytes or oligodendrocyte precursor 
cells (OPC) by immunohistology stainings on vibratome sections with the oligodendro-
cyte lineage marker Olig2 (Fig. 8A). Single mEos2 puncta not associated with nuclei 
were expected to reside in cellular processes and cytoplasmic compartments of myelin 
such as the innermost and outermost myelin wrap, as well as in paranodal loops. 
Quantification revealed that the majority of Olig2 positive nuclei were associated with a 
perinuclear mEos2 signal. 60-80% of the oligodendrocyte lineage cells in the corpus 
callosum, the cerebellar white matter, the anterior commissure and the cortex showed 
colocalization with mEos2 puncta (Fig. 8B). 
 
 




                   
Fig. 8: The majority of Olig2+ cells in Cnp-mEos2-PTS1 transgenic mice show perinuclear mEos2+ 
puncta 
(A) Immunostaining for the nuclear oligodendrocyte line-age marker Olig2 (red) on Vibratome sections 
shows frequent association of oligodendroglial lineage cells with perinuclear mEos2+ puncta. (B) Quantifi-
cation of Olig2+ nuclei with perinuclear mEos2 signal in the cerebellar white matter (CB) anterior commis-
sure (AC) corpus callosum (CC) and in the cortex (CTX) reveals ≥ 60% of transgene expressing oligoden-
drocyte lineage cells. (Mean + SD; n = 3) Scale bar: 50 µm  
 
To exclude transgene expression in other cell types of the CNS immunostainings on 
vibratome sections were performed with antibodies against marker proteins for neurons 
(NeuN), astrocytes (GFAP) and microglia (IBA1; Fig. 9). Perinuclear distribution of mE-
os+ vesicles was never found in close association with any of these marker proteins, 
indicating exclusive transgene expression in oligodendrocytes and probably oligoden-
drocyte precursor cells in the brain.  
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Fig. 9: mEos2+ puncta are absent from astrocytes, microglia, and neurons 
Immunohistochemical labeling on vibratome sections from 2-month-old Cnp-mEos2-PTS1 transgenic mice 
for (A) Astrocytes (GFAP; red) (B) Microglia (IBA1; red) and (C) Neurons (NeuN; red) show the absence of 
perinuclear mEos2+ puncta (green) from cells other than oligodendrocyte lineage cells. Scale bar: 50 µm 
 
3.2.3 Peroxisomal targeting of mEos2-SKL 
The C-terminal tri-peptide Ser, Lys, Leu serves as a peroxisomal targeting sequence 
(PTS), which is recognized and shuttled into the peroxisome by the soluble recycling 
receptor PEX5. Punctate distribution of mEos2 fluorescence indicates vesicular distri-
bution of transgenic mEos2 protein. To confirm the peroxisomal localization two peroxi-
somal marker proteins were chosen for immunohistochemical co-labeling on vibratome 
sections of 2-month-old Cnp-mEos2-PTS1 transgenic animals. Acetyl-CoA acyltrans-
ferase (ACAA1; Fig. 10A) is an intraperoxisomal enzyme involved in peroxisomal β-
oxidation. The peroxisomal membrane protein 70 (PMP70; Fig. 10B) is an ABC-
transporter, an integral membrane protein of peroxisomes. Both marker proteins (Fig. 
10, red) showed substantial colocalization with the mEos2 signal (Fig. 10, green). Pe-
roxisomes that were positive for peroxisomal markers, but not for mEos2 are likely to 
reside in other cell types than oligodendrocyte lineage cells. To exclude targeting of the 
transgene to other organelles than peroxisomes, mitochondria were visualized by stain-
ing for mitochondrial ribosomal protein S21 (MRP-S21; Fig. 10A) and lysosomes by the 
detection of lysosome-associated membrane protein 1 (Lamp1; Fig. 10D). mEos2 sig-
nal was never found to colocalize with any of these markers proteins.  




                             
Fig. 10: mEos2 targets exclusively to peroxisomes in Cnp-mEos2-PTS1 mice 
Immunohistochemical co-labeling on vibratome sections with the intraperoxisomal marker proteins (A) 
Acetyl-CoA acyltransferase (ACAA1; red) and (B) the peroxisomal membrane protein 70 (PMP70; red) 
show peroxisomal location of the mEos2 signal (green). Co-staining for (C) the mitochondrial ribosomal 
protein S21 (MRP-S21; red) and (D) the lysosome-associated membrane protein 1 (Lamp1; red) did not 
show colocalization, excluding mistargeting of the mEos2 protein to these organelles. DAPI-stained nuclei 
are shown in blue. Scale bar: 5 µm.  
 
3.2.4 Photoconversion of mEos2 
The pH may have an impact on fluorescent proteins (FP). Peroxisomal pH has been 
shown to differ from the cytosol and may thus result in altered mEos2 performance 
(Dansen et al. 2000; Jankowski et al. 2001). To optimize mEos2 visualization the actual 
excitation and emission spectra of intraperoxisomal mEos2 in live Oli-neu cells, an oli-
godendroglial cell line, was determined. Cells were transfected with the same construct 
used for transgenic mouse generation. Two days after transfection a lambda scan was 
conducted on live cells incubated at 37°C and 5% CO2 concentration with excitations 
between 470 nm and 670 nm and a 10 nm step-width. The 2D contour plot shows max-
imum emission at 530 nm when excited at 509 nm (Fig. 11). This is comparable to the 
published spectral properties with a maximum emission at 519 nm upon excitation at 
506 nm (McKinney et al. 2009).  
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Fig. 11: 2D contour plot from a λ scan of Cnp-mEos2-PTS1 transfected cells confirms chromophore 
functionality 
X-axis shows emission peak at 530 nm upon excitation at 509 nm (y-axis), which is comparable to the 
published spectral properties.   
 
Photoconvertible FPs enable tracing of subpopulations by pulse-chase experiments. 
The mEos2 protein is photoconverted by ≈370 nm light irradiation, which catalyzes the 
cleavage of an amide bond between two amino acids in the chromophore resulting in a 
red shift of fluorescence emission. A protocol for photoconversion of the mEos2 protein 
in live cells was adapted on an inverted microscope equipped for live-cell imaging with 
live Oli-neu cells expressing the Cnp-mEos2-PTS1 construct or fibroblasts expressing 
mEos2-PTS1. Conversion from green to red was achieved by irradiation with a Dapi 
Filter cube (340 nm to 390 nm) at high output intensity levels of the mercury short arc 
illumination source. Following ≈370 nm light exposure single red peroxisomes were 
readily detectable, but absent from regions not exposed to ≈370 nm light (Fig. 12A). 
The protocol was designed such that only a portion of the intraperoxisomal mEos2 pro-
tein was switched to red fluorescence. Conversion of the total mEos2 pool resulted in 
pronounced bleaching and phototoxicity. Using a 63x objective 1,200 ms excitation 
resulted in roughly the same emission intensity of red and green. The employment of 
an adjustable rectangular diaphragm allowed photoconversion of a discrete number of 
peroxisomes while the majority remained unswichted as shown using fibroblasts (Fig. 
12B).  
 




Fig. 12: Photoconversion of live cells expressing mEos2-PTS1 
(A) Cultured Oli-neu cells transfected with Cnp-mEos2-PTS1 exhibit strong green, but no red fluores-
cence. Upon irradiation with ≈370 nm light punctate red fluorescence is detectable, which colocalizes with 
green mEos2+ puncta. Scale bar: 5 µm (B) A subpopulation of peroxisomes can be photoconverted by 
using a rectangular diaphragm (indicated by dashed line in magnification) in live fibroblasts expressing 
mEos2-PTS1. Scale bar: 10 µm 
 
The same photoconversion protocol was applicable to PFA fixed tissue (Fig. 13). With 
lower magnification objectives ≈370 nm light exposure time had to be increased. Con-
version was achieved in different brain areas of fixed tissue such as CC and CB (Fig. 
13A, B). 
 
Fig. 13: Photoconversion of vibratome sections from Cnp-mEos2-PTS1 mouse brains 
The corpus callosum (A) and the cerebellum (B) are depicted before irradiation with ≈370 nm light (left). 
Red fluorescence is basically absent except for typical, but weak autofluorescence. After photoconversion 
the green signal is reduced in favor of red fluorescence (right). Insets show magnification of cerebellar 
white matter. Scale Bar: 200 µm 
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3.2.5 Cnp-mEos2-PTS1 expression in oligodendrocytes is not toxic  
High amounts of transgene expression can pose a challenge to organisms. To rule out 
possible toxic effects of the substantial amount of mEos2 in peroxisomes, 12-month-old 
Cnp-mEos2-PTS1 transgenic animals were analyzed for cell degeneration and gliosis. 
The amount of apoptotic cells as observed by Hematoxylin and eosin (H&E) staining 
and terminal transferase dUTp nick end labeling (TUNEL) was unaltered between WT 
and transgenic animals (not shown). Astrogliosis and microgliosis are often early re-
sponses to CNS damage (Burda & Sofroniew 2014). Neither astrocytes (GFAP) nor 
microglia (IBA1) showed differences in morphology, density or distribution as observed 
by immunohistochemical analysis in different brain areas (Fig. 14). Cage behavior was 
observed at regular intervals and did not show abnormalities up to 12 months of age 
(not shown).  
 
 
Fig.14: 12-month-old Cnp-mEos2-PTS1 mice show no signs of reactive gliosis 
Visualization of the microglial surface marker protein IBA1 (A) and the astroglial fibrillary acid protein 
GFAP (B) by immunofluorescent labeling reveals no differences between WT and transgenic mice regard-
ing distribution, morphology or expression in the corpus callosum (top), the cerebellum (middle) and the 
cortex (bottom). Scale bars: 50 µm.  
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3.3 Reduced peroxisomal abundance and slowed peroxisomal 
turn-over in tgCnpCre/Wt*Mfp2 -/- mice  
Reduction in peroxisomal abundance has been observed in human skin fibroblasts 
from patients with impaired β-oxidation (Chang et al. 1999). To investigate whether 
CnpCre/Wt*Mfp2-/- mutants exhibit a similar phenomenon in myelinating glial cells they 
were crossbred to Cnp-mEos2-PTS1 mice (hereafter referred to as tgCnpCre/Wt*Mfp2-/- 
(tgCnpCre/Wt*Mfp2-/-) and peroxisomal numbers were analyzed by wide-field and super 
resolution microscopy. Moreover, the employment of a photoconvertible fluorescent 
protein enabled pulse-labeling of peroxisomal populations to investigate whether perox-
isome turnover is altered due to impaired peroxisomal β-oxidation.  
 
3.3.1 Reduced peroxisomal abundance in tgCnpCre/Wt*Mfp2-/- mice 
Vibratome sections of PFA-fixed brains from 1 month (juvenile), 2 months (young adult) 
and ≥ 16 months (aged) old animals were taken and nuclei were stained using ToPro-
3. Z-stacks were acquired on a widefield microscope and oligodendroglial peroxisomes 
were quantified using Imaris. ToPro-3 positive nuclei associated with mEos2 positive 
peroxisomes were considered oligodendrocytes. Peroxisome number per oligodendro-
cyte was unaltered at 1 month of age (Fig. 15A), but already significantly reduced at 2 
months and further decreased at 16 months to less than 50% of Cnp-mEos2-
PTS1*Mfp2flox/flox (hereafter termed CTR) levels (Fig. 15B). In addition, 16-month-old 
mutants revealed a tendency to fewer mEos2 positive oligodendrocytes (Fig. 15C), 
together resulting in a peroxisomal density resembling only 1/3 of control levels. Juve-
nile CTR mice exhibited more peroxisomes than young adult mice, but overall peroxi-
some numbers remained unaltered between young adult and aged CTR mice 
(Fig. 15D). Strikingly, the reduction of peroxisomes in the cellular periphery of oli-
godendrocytes was even more pronounced than that of the perinuclear organelles in 
tgCnpCre/Wt*Mfp2-/-. This was determined using an automated process to distinguish 
somatic (within a 4 µm radius from the nucleus; Fig. 15E; depicted in green) from pe-
ripheral peroxisomes (more than 4 µm distance from the nucleus; Fig. 15E; depicted in 
yellow). Already at 1 month a tendency to less peripheral peroxisomes was observed, 
at 2 months half of the peripheral peroxisomes had disappeared, and at 16 months 
only 20% compared to CTR were left. The strong reduction of peripheral peroxisomes 
might not only affect myelin maintenance, but as well have indications for the putative 
axonal support by myelin peroxisomes.  
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Fig. 15: Reduction of peroxisomes in tgCnpCre/Wt*Mfp2-/- mutants  
(A) Vibratome sections of transgenic CTR and mutant mice show normal numbers of peroxisomes (green) 
at 1 month, but a decrease of peroxisomes in two and sixteen-month-old animals; Nuclear stain with To-
Pro-3 (red). (B) Quantification of peroxisomes per oligodendrocyte prove a significant reduction of about 
25% in 2 months, and more than 50% in ≥ 16-month-old mutants. (C) Aged tgCnpCre/Wt*Mfp2-/- animals 
show a tendency to less mEos2 positive oligodendrocytes. (D) The combination of fewer mEos2+ oli-
godendrocytes and less peroxisomes per cell results in a total decrease of more than 2/3 of peroxisomes 
in ≥ 16-month-old mutants per 100µm3. (E) Examples for the quantification of peroxisomes and the subdi-
vision into somatic peroxisomes (within a 4 µm radius from the nucleus; depicted in green) and peripheral 
peroxisomes (> 4µm away from the nucleus; depicted in yellow) in Imaris (bottom). The corresponding 
fluorescent images from ≥ 16-month-old animals are shown above. (F) Quantification of peripheral peroxi-
somes shows a decrease of about 80% in mutants. (CTR n ≥ 3, mutant n ≥ 3; Mean + SD). Scale bar: 10 
µm.  
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Histological abnormalities and reactive gliosis in aged CnpCre/Wt*Mfp2-/- mice were most 
prominent in the frontal CC. The caudal CC showed no obvious pathology (see Fig. 
4A). To analyze whether peroxisomal changes were confined to brain areas with se-
vere pathology, vibratome brain sections of 2 and ≥ 16-month-old tgCnpCre/Wt*Mfp2-/- 
and appropriate CTR mice were analyzed with respect to peroxisome number and dis-
tribution (Fig. 16A). 
Quantification of images acquired by wide-field microscopy revealed that the decrease 
of peroxisomes per area was equivalent between the frontal and the caudal corpus 
callosum at both time points in mutants (Fig. 16B). Also reduction of peripheral peroxi-
somes was comparable. Thus altered peroxisome numbers are not confined to brain 
regions with overt histological alterations.  
      
 
Fig. 16: Reduction of peroxisomes in areas without overt pathology  
(A) Vibratome sections of tgCnpCre/Wt*Mfp2-/- animals stained for ToPro-3 (red) show a comparable de-
crease in peroxisome number (green) between the frontal and the caudal CC. (B) Quantifications confirm 
no differences in reduction of neither peroxisome number per area nor peripheral peroxisomes between 
affected and unaffected brain regions. (CTR n ≥ 3, mutant n ≥ 3; Mean + SD). Scale bar: 10 µm.  
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3.3.2 tgAbcd1-/- mutants do not exhibit decreased peroxisome abundance 
X-linked Adrenoleukodystrophy is caused by mutations in the peroxisomal membrane 
protein ABCD1, which mediates the import of very long chain fatty acids (VLCFA) into 
peroxisomes for subsequent degradation by β-oxidation. About one third of X-ALD pa-
tients develop childhood cerebral ALD exhibiting similarities with other disorders 
caused by peroxisomal β-oxidation defects. Abcd1-/- mice however fail to develop a 
cerebral phenotype, but only show peripheral nervous system symptoms. The reduc-
tion of peroxisomes in MFP2-deficient oligodendrocytes precedes typical neurodegen-
erative features by several month. Therefore, also Abcd1-/- mice were analyzed for pe-
roxisomal abundance in brain OL. We analyzed vibratome sections of ≥ 16-month-old 
Cnp-mEos2-PTS1*Abcd1-/- (tgAbcd1-/-; Fig. 17A). The total peroxisome number per 
area was not altered in tgAbcd1-/- mutants compared to CTR. Furthermore, the quanti-
fication of peripheral peroxisomes revealed no reduction.  
 
 
Fig. 17: Peroxisome reduction is not a feature of tgAbcd1-/- mutants 
(A) Vibratome sections of ≥ 16-month-old CTR and tgAbcd1-/- mice stained for ToPro-3 (red) show no 
differences in peroxisomal number (green; B) Quantifications confirm that neither peroxisome number per 
area nor peripheral peroxisomes are reduced in transgenic Abcd1-/- compared to CTR animals. (CTR n ≥ 
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3.3.3 MFP2-deficient peroxisomes differ in shape and size 
Peroxisomes in aged transgenic CnpCre/Wt*Mfp2-/- mice appeared to differ in size and 
shape from peroxisomes in corresponding CTRs when analyzed by wide-field micros-
copy. Since the diameter of brain peroxisomes (0.1- 0.25 µm; Kovacs et al. 2001) is 
usually smaller than the diffraction limit of light microscopes we applied the super-
resolution microscopy technique STED (Stimulated emission depletion; in collaboration 
with Dr. Katrin Willig) to further characterize peroxisomes in aged mutants. Vibratome 
sections of immersion fixed brain tissue were taken from CTR and tgCnpCre/Wt*Mfp2-/- 
animals. mEos2 proved to be suitable for visualization by STED microscopy with re-
gard to quantum yield and photostability (Fig. 18A). Peroxisomal size was increased in 
tgCnpCre/Wt*Mfp2-/- mutants and peroxisomal shape was more variable (Fig. 18B). En-
largement of the organelles may be the result of either enhanced growth, or normal 
growth rates, but lack of subsequent fission or degradation. Hindered fission might also 
explain reduced sphericity of mutant peroxisomes.  
                   
Fig. 18: STED microscopy confirms increased size and altered shape of tgCnpCre/Wt*Mfp2-/- peroxi-
somes 
(A) Images of Vibratome sections from ≥ 16-month-old CTR and mutant animals were acquired by STED 
microscopy and showed an increase in size of peroxisomes and a more diverse morphology. (B) Quantifi-
cation with Imaris software confirmed an increase from 0.1 µm2 in CTR to around 0.13 µm2 in mutant mice, 
which also showed decreased circularity. (CTR n ≥ 3, mutant n ≥ 3; Mean + SD) Scale bar: 2 µm and scale 
bar in magnified image: 1 µm. 
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3.3.4 Peroxisomal degradation and proliferation in oligodendrocytes  
To analyze peroxisomal turnover in vitro, oligodendrocyte precursor cells (OPCs) were 
prepared. Individual oligodendrocytes (OL) possessing green mEos2+ peroxisomes 
were pulse-labeled by ≈370 nm light irradiation, upon which virtually all peroxisomes 
showed both red and residual green fluorescence (d0; Fig. 19A). The same cells were 
monitored up to day 8 after photoconversion and peroxisomes were quantified. In 
CTRs number of peroxisomes exhibiting red fluorescence steadily decreased over time 
to about 30% at the final time point compared to 100 % at time point d0 (Fig. 19B). Re-
duction of pulse-labeled peroxisomes is likely caused by autophagic degradation (pex-
ophagy). In addition, repeated fission events or asymmetrical fission might cause dilu-
tion of the red signal to below detection limit. This might lead to artificial loss of 
detectable red peroxisomes.  
Decrease of red peroxisomes went along with a steady increase of peroxisomes exhib-
iting green, but no red mEos2 fluorescence, which accounted for 76% of all peroxi-
somes at T8 (Fig. 19B). Peroxisomes containing green, but no red mEos2 fluorescence 
probably arouse by de novo synthesis, but could as well originate from subsequent 
fission events or asymmetrical fission going along with import of newly synthesized 
mEos2 protein.  
Unlike expected no increase of pulse-labeled peroxisomes due to peroxisomal fission 
could be observed when looking at the average numbers. However, analysis of individ-
ual cells revealed that about 40% of the OL showed an increase in red fluorescent pe-
roxisomes one or two days after photoconversion (Fig. 19C). This confirms that peroxi-
somal proliferation via fission occurs in OLs and beyond demonstrates that at least a 
limited number of fission events can be detected by our assay in CTR OL. Interestingly 
the reappearance of only green mEos2 positive peroxisomes did not differ in OL with or 
without peroxisomal fission events (Fig. 19C).  
Taken together these results indicate that around 70% of the total peroxisomal pool in 
oligodendrocytes is turned over in a time frame of eight days, which corresponds to a 
peroxisomal half life of about 4.5 days. However, it cannot be clearly differentiated 
whether the whole organelle or the peroxisomal protein content is turned over. Analysis 
of OL subpopulations proved the detectability of fission in OLs by our assay and fur-
thermore indicates an independent regulation of fission and de novo synthesis.  
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Fig. 19: Peroxisomal turnover in CTR oligodendrocytes  
(A) Representative images of a CTR OL immediately after photoconversion (T0; left) and 8 days later (T8; 
right) show a marked decrease of peroxisomes exhibiting red mEos2 fluorescence at the later timepoint. 
Scale Bar: 50 µm (B) Quantifications revealed that the number of pulse-labeled peroxisomes decreases 
rapidly to around 30% at day 8, normalized to day 0, while the number of only green peroxisomes increas-
es steadily to 75% at day eight. (C) About 40% of OLs show peroxisomal fission of pulse-labeled peroxi-
somes (left). The number of newly formed only green peroxisomes increases independently of fission 
events (right). (≥ 3 independent experiments with ≥ 10 cells analyzed per experiment; Mean + SD) 
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3.3.5 Slowed peroxisomal turnover in tgCnpCre/Wt*Mfp2-/- 
The observed peroxisomal alterations in tgCnpCre/Wt*Mfp2-/- mutants brains cannot be 
explained by the defect in peroxisomal β-oxidation. Impairment of the β-oxidation 
pathway may however influence peroxisomal turnover indirectly via alterations of pe-
roxisomal biogenesis or degradation. Therefore, OL cultures were generated from CTR 
and mutant mice and pulse-label experiments conducted as described before. Both, 
CTR and mutant cells developed sheet-like structures as visualized by staining for 
Myelin basic protein (MBP; Fig. 20A). Comparable to the in vivo situation, mature 
tgCnpCre/Wt*Mfp2-/- cells harbored less peroxisomes (Fig. 20B). The number of red fluo-
rescent mEos2 peroxisomes was more stable than in CTRs and even increased slightly 
up to day 2. Eight days after photoconversion around 95% of pulse-labeled peroxi-
somes were still detectable, implying impaired degradation of peroxisomes or possibly 
also a reduced number of fission events in mutant cells (Fig. 20E). Furthermore, the 
reappearance of peroxisomes containing only green mEos2 fluorescence was marked-
ly reduced in mutant OL, accounting for less than 20% of all peroxisomes at the last 
time point analyzed (Fig. 20F). mEos2 fluorescence increased over time indicating con-
tinuous protein import into peroxisomes (Fig. 20C). Impaired de novo synthesis, but 
also less fission events could account for the reduced reappearance of only green pe-
roxisomes. Taken together peroxisomal aging is evidently increased in MFP2-deficient 
mutants compared to control oligodendrocytes.  
2´,3´-cyclic nucleotide 3´-phosphodiesterase (CNP) accounts for about 4% of CNS my-
elin proteins. Heterozygous depletion of Cnp has been shown to be associated with 
mild axonal degeneration in aged mice (> 24 months; Hagemeyer et al. 2012). Fur-
thermore Cre expression was related to increased oxidative stress and peroxisome 
proliferation in mice (Xiao et al. 2013). To exclude that reduced Cnp gene dosage or 
heterozygous Cre expression causes the effects observed in tgCnpCre/Wt*Mfp2-/- cells, 
Cnp-mEos2-SKL*CnpCre/Wt (hereafter referred to as tgCnpCre/Wt) animals were generat-
ed. Pulse-labeling experiments in OL were conducted and peroxisomes quantified on 
day 2, 4 and 8 after photoconversion. At two days after photoconversion a transient 
increase in red mEos2 positive peroxisomes in tgCnpCre/Wt animals was observed, pos-
sibly due to Cre mediated oxidative stress, that was absent from CTR cells (Fig. 20E). 
Already at four days after photoconversion the number of pulse-labeled peroxisomes 
was indistinguishable from CTR cells. The reappearance of newly formed peroxisomes 
was comparable between tgCnpCre/Wt and CTR cells (Fig. 20 F). tgCnpCre/Wt showed a 
high turnover of peroxisomes similar to CTR cells. Hence, neither reduced Cnp gene 
dosage nor heterozygous Cre expression account for the changes observed 
tgCnpCre/Wt*Mfp2-/- OLs.  
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Fig. 20: tgCnpCre/Wt*Mfp2-/- OL show reduced peroxisomal numbers and slowed turnover  
(A) Immunostaining for Myelin basic protein (MBP) in CTR and tgCnpCre/Wt*Mfp2-/- OLs 8 days after plating 
demonstrates myelin sheet-like formation. Scale Bar: 50 µm (B) Imaris quantification of mEos2 positive 
peroxisomes shows a decrease in peroxisomal abundance of about 50% in day 8 mutant OLs. (C) Analy-
sis of intraperoxisomal mEos2 signal in tgCnpCre/Wt*Mfp2-/- reveals constant increase in fluorescence inten-
sity indicating continuous protein import. (D) Representative images of tgCnpCre/Wt*Mfp2-/- and tgCnpCre/Wt 
OLs immediately after photoconversion (T0; left) and 8 days later (T8; right). tgCnpCre/Wt OLs show a de-
crease of peroxisomes exhibiting red mEos2 fluorescence at T8 comparable to CTRs. In tgCnpCre/Wt*Mfp2-/- 
the majority of peroxisomes still exhibits both green and red mEos2 fluorescence at T8. Scale Bar: 50 µm 
(E) Quantification confirms enhanced stability of the number of pulse-labeled peroxisomes in 
tgCnpCre/Wt*Mfp2-/- OLs (96%), whereas tgCnpCre/Wt (17%) compare to CTR cells (27%; triangle indicates P-
value < 0.05 in the tgCnpCre/Wt cells; F) The reappearance of peroxisomes exhibiting only green, but no red 
mEos2 fluorescence is reduced in tgCnpCre/Wt*Mfp2-/- (19%), compared to tgCnpCre/Wt (86%), and CTRs 
(76%). (≥ 3 independent experiments with ≥ 10 cells analyzed per experiment and genotype; Mean + SD).  
 
3.3.6 3-Methyladenine treatment reduces autophagic degradation and peroxi-
somal biogenesis  
Pulse-label experiments in CTR oligodendrocytes showed steady reduction of pulse-
labeled red mEos2-positive peroxisomes. To investigate whether this is mainly caused 
by autophagy or by fission, peroxisomal degradation was inhibited by application of 3-
Methyladenine (3-MA), an autophagy blocker (Iwata et al. 2006; Kaushik et al. 2008). 
Peroxisome stability was markedly increased by 3-MA treatment as depicted in (Fig. 
21A). Quantification of pulse-labeled peroxisomes revealed a nearly stable number of 
labeled peroxisomes up to day 4 and a final decrease by only 30% compared to 70% in 
untreated CTRs (Fig. 21B). The impaired degradation of peroxisomes upon 3-MA 
treatment indicates that the majority of peroxisomes in CTR cells is degraded via 
macroautophagy. Other degradative pathways, but also dilution of the photoconverted 
protein by fission, photo-bleaching, or intraperoxisomal protein degradation may con-
tribute to the residual loss of labeled peroxisomes in 3-MA and CTR cells.  
Remarkably 3-MA treatment also drastically reduced the reappearance of only green 
peroxisomes to about 20% at the final time-point compared to more than 75% in CTR 
OL (Fig. 21B). This suggests a coupling of peroxisomal biogenesis to autophagic deg-
radation, though it cannot yet be excluded whether 3-MA has a direct effect on peroxi-
somal biogenesis. These observations may imply that in tgCnpCre/Wt*Mfp2-/- oligoden-













Fig. 21: Reduced autophagic degradation also impairs peroxisomal biogenesis  
(A) Representative images of CTR OLs treated with 10 mM 3-Methyladenin (3-MA). Images acquired 
immediately after photoconversion (T0; left) and 8 days later (T8; right) show a high amount of peroxisomes 
exhibiting both green and red mEos2 fluorescence at T8 resembling tgCnpCre/Wt*Mfp2-/-. Scale Bar: 50 µm. 
(B) Quantification confirms enhanced stability of the number of pulse-labeled peroxisomes in 3-MA treated 
OLs (72%) compared to CTRs (27%). Reappearance of peroxisomes exhibiting only green, but no red 
mEos2 fluorescence is impaired in 3-MA treated cells (21%) compared to CTRs (76 %). (≥ 3 independent 
experiments with ≥ 10 cells analyzed per experiment; Mean + SD). 
 




Peroxisomal biogenesis disorders (PBDs) are caused by mutations in peroxins that 
result in the loss of peroxisomal function. Patients often exhibit severe central nervous 
system and hepato-renal symptoms. The former comprises cortex and cerebellum mal-
formations, peripheral neuropathy, and inflammatory demyelination (Waterham 2016). 
Interestingly, patients carrying mutations only in single enzymes or transporters in-
volved in peroxisomal β-oxidation often show common hallmarks with PBDs unlike pa-
tients with impaired peroxisomal α-oxidation or plasmalogen synthesis, who present 
with a distinct clinical picture. This indicates a common pathomechanism for both types 
of disorders, those caused by impairment of peroxisomal b-oxidation and those caused 
by peroxisomal biogenesis defects. Further indications for an analog disease etiology 
derive from mice lacking peroxisomal function from oligodendrocytes (CnpCre/Wt*Pex5-/-
). These mutant mice exhibit inflammatory subcortical demyelination reminiscent of the 
cerebral pathology of patients affected with cerebral ALD, which is caused by muta-
tions in a peroxisomal transporter for very long chain fatty acids. To analyze whether 
certain cell types play a decisive role for neurodegeneration, peroxisomal function was 
depleted from astrocytes (GfapCre/Wt*Pex5-/-), neurons (NexCre/Wt*Pex5-/-) and oligoden-
drocytes (CnpCre/Wt*Pex5-/-). While GfapCre/Wt*Pex5-/- and NexCre/Wt*Pex5-/- exhibited no 
overt phenotype CnpCre/Wt*Pex5-/- showed demyelination, axonal degeneration and re-
active gliosis similar to mice lacking peroxisome function from all brain cells (Nestin-
Cre/Wt*Pex5-/-) albeit ameliorated. This indicates that oligodendroglial peroxisomes play a 
crucial role for myelin maintenance and axonal integrity. To investigate the role of pe-
roxisomal β-oxidation in oligodendrocytes CnpCre/wt*Mfp2-/- mice were generated (Ver-
heijden et al. 2013). Here, we analyzed aged (≥ 16 month) CnpCre/wt*Mfp2-/- mice to 
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4.1 CnpCre/Wt*Mfp2!/! display a late-onset subcortical demye-
lination reminiscent of mice with peroxisomal biogenesis 
defects in oligodendrocytes 
Mutations in enzymes or transporters of the peroxisomal β-oxidation, such as ACOX1 
or ABCD1, often exhibit rather mild phenotypes in mice with mainly hepato-renal prob-
lems, but no overt brain pathology. The corresponding mutations in humans show a 
clinical presentation similar to PBD patients, but with later onset, indicating that the 
short life-span of mice possibly impedes the development of neurodegeneration. The 
multifunctional protein 2 (MFP2) shows the most severe pathology throughout peroxi-
somal β-oxidation defects in man. This is reflected in MFP2-deficient mice, which ex-
hibit a neurodegenerative pathology including cerebellar atrophy and inflammation. 
Unlike patients, mutant mice do not develop inflammatory cerebral demyelination be-
fore they perish around 6 months of age, likely due to the peroxisomal defects in liver 
(Baes 2000; Huyghe et al. 2006). Nestin*Mfp2-/- mice lacking MFP2-function from all 
brain cells, except microglia, were developed to concentrate on the role of peroxisomal 
β-oxidation in the brain uncoupled from liver defects. These mice also show a neuro-
degenerative pathology, albeit with reduced neuroinflammation and enhanced lifespan 
compared to conventional MFP2-knockout mice. This milder brain pathology may be 
attributed to the preservation of peroxisomal β-oxidation in microglial cells in this 
mouse model. 
First analyses of CnpCre/Wt*Mfp2-/- mice (hereafter referred to as mutants) published by 
Verheijden et al. showed neither overt phenotypic alterations nor structural myelin 
changes compared to controls in animals ≤ 12 month of age (Verheijden et al. 2013). 
This indicates that β-oxidation in oligodendrocytes is not crucial for initial myelination. 
This is in line with observations from CnpCre/Wt*Pex5-/- mice lacking peroxisomal function 
from oligodendrocytes completely, but displaying normal myelin until the age of 2 
months. When analyzing CnpCre/Wt*Mfp2-/- mice, we detected an abnormal loss in 
weight gain starting around 12 months, indicating a possible onset of disease. Motori-
cal impairment as evidenced by measuring behavioral tasks started around 15 months 
of age. Histologic and electron microscopic analysis at ≥16 months revealed subcorti-
cal demyelination in mutants, starting in the frontal corpus callosum (genu of corpus 
callosum). This was accompanied in the same brain region by signs of axonal patholo-
gy, i.e. abnormal swellings and reduced axonal abundance. Furthermore, reactive glio-
sis and infiltration of peripheral CD3-positive T-lymphocytes were revealed specifically 
in demyelinating lesion sites. Histological abnormalities were mainly concentrated in 
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the genu of corpus callosum, which is also primarily affected in mice without functional 
peroxisomes in oligodendrocytes (CnpCre/Wt*Pex5-/-).  
The question remains as to what causes region specific onset of pathology in the 
frontal corpus callosum (CC) in CnpCre/Wt *Mfp2-/-. Interestingly, also in CnpCre/Wt*Pex5-/- 
mutants the genu of corpus callosum is mainly affected. Similarly, cuprizone treatment 
in rodents showed most severe demyelination in the CC and cALD patients often ex-
hibit initial demyelinating lesions in the caudal CC (Engelen et al. 2012; Steelman et al. 
2012). So far the cause for the region specificity remains enigmatic, but an activity de-
pendency might be envisioned. The CC has been shown to utilize higher amounts of 
glucose in rats, a cross species comparison could not confirm this however (Sokoloff 
1977; Karbowski 2007). 
It is not resolved yet, which peroxisomal β-oxidation substrates are important with re-
spect to brain pathology in MFP2-deficiency. This is possibly further complicated by the 
overall limited knowledge on β-oxidation substrates in the CNS (Baes & Van Veldhoven 
2012). However, a biochemical hallmark of MFP2-deficiency is the accumulation of 
several peroxisomal β-oxidation substrates such as VLCFA, bile acid intermediates, 
and pristanic acid (Ferdinandusse et al. 2006). In contrast, docosahexaenoic (DHA), 
the most abundant polyunsaturated fatty acid in the brain, is a product of peroxisomal 
β-oxidation, which is reduced when peroxisomal β-oxidation is impaired. DHA is a pre-
cursor for bioactive molecules involved in inflammation and is also involved in peroxi-
somal biogenesis (see also section 1.4.2; Itoyama et al. 2012; Braverman & Moser 
2012). 
A prime suspect for triggering brain disease in peroxisomal β-oxidation deficiency is the 
accumulation of VLCFAs, which is also the major biochemical abnormality in human X-
linked Adrenoleukodystrophy, whose patients as well suffer from cerebral demye-
lination. VLCFA are incorporated into complex lipids such as gangliosides and phos-
phatidylcholine, and into branched chain FA, which are highly abundant in brain tis-
sues. They are implied to enhance oxidative stress, possibly destabilize membranes, 
and lately have also been suggested to exert a negative effect on autophagy (Hein et 
al. 2008; Baarine, Ragot, et al. 2012; Baarine, Andréoletti, et al. 2012; Launay et al. 
2014). However, increased VLCFA levels are also found in unaffected patient tissue 
and in brains of ABCD1-deficient mice, which do not develop a cerebral pathology, 
indicating that VLCFA accumulation itself not necessarily results in pathology (Forss-
Petter et al. 1997).  
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The accumulation of branched chain FA (BCFA), especially phytanic and pristanic acid, 
has detrimental effects on the central nervous system, which is known from another 
peroxisomal disease caused by impaired α-oxidation, called Refsum disease 
(Schönfeld & Reiser 2016). Both, phytanic and pristanic acids, are also mildly elevated 
in MFP2-deficient animals. However, since BCFA-rich diets increased plasma concen-
trations, but did not aggravate brain lesions, only a minor role is attributed to BCFA in 
the pathology caused by MFP2-deficiency (Huyghe et al. 2006).  
The critical role of peroxisomal β-oxidation described above led to the speculation, 
whether lack of this pathway itself is primary responsible for brain disease also in 
PBDs, i.e. when peroxisomal function is completely absent. Although, the pattern as 
well as the hallmarks of neurodegeneration were reminiscent of CnpCre/Wt*Pex5-/- the 
severity and age of disease-onset varied significantly between CnpCre/Wt*Mfp2-/- and 
CnpCre/Wt*Pex5-/-, with ≥ 16 month and 3-6 month respectively. Similarly, mice with ei-
ther generalized or neural MFP2-deficiency, also show an alleviated phenotype com-
pared to mice lacking peroxisomal function in the corresponding tissues completely (i.e. 
conventional Pex5-/- and NestinCre/Wt*Pex5-/- mice), indicating that peroxisomes carry out 
additional functions important for proper cell function (Baes et al. 1997; Hulshagen et 
al. 2008).  
So far only mice without functional peroxisomes in myelinating glial cells 
(CnpCre/Wt*Pex5-/-) have been observed to exhibited callosal demyelination, a major 
hallmark of peroxisomal biogenesis defects and peroxisomal β-oxidation deficiency in 
humans. The here, analyzed CnpCre/Wt*Mfp2-/- animals is the first mouse model with a 
specific genetic impairment of peroxisomal β-oxidation that develops a subcortical de-
myelination reminiscent of the human pathology. This mouse model enables to investi-
gate the possible effect of impaired peroxisomal β-oxidation on other peroxisomal met-
abolic pathways, on peroxisomal biogenesis, and on demyelination. Thus, it may also 
allow to study the prevention of secondary peroxisomal defects in the future, that may 
help preventing or delaying disease.  
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4.2 Cnp-mEos2-PTS1 mice enable cell type-specific analysis of 
peroxisomes  
The generation of the Cnp-mEos2-PTS1 transgenic mouse facilitates oligodendrocyte 
(OL) specific analysis of peroxisomes. The choice of a photoconvertible fluorescent 
protein significantly broadens the spectrum of applications, as it enables pulse-chase 
approaches that allow the investigation of peroxisomal biogenesis and peroxisomal 
degradation. The tripeptide peroxisomal targeting sequence, SKL (serine-lysine-
leucine), efficiently and specifically mediates peroxisomal import of the transgenic pro-
tein evidenced by mEos2 signal in peroxisomes, but absence from other organelles.  
The Cnp promoter is expressed starting around embryonic day 13 in mice and allows 
the detection of peroxisomes from postnatal day 1 (P1) on, enabling the investigation of 
peroxisomes during development (Gravel et al. 1998). At P7 fluorescent peroxisomal 
structures were detectable throughout many brain regions and at p14 the final expres-
sion pattern was established. A high efficiency of oligodendrocytic targeting was proven 
by colocalization studies with the oligodendrocyte lineage marker protein Olig2. In 
white matter structures, but also in oligodendrocytes of grey matter, approximately 60-
80% of Olig2 positive cells were associated with perinuclear mEos2 positive peroxi-
somes. Olig2 is a marker protein not only for mature OL, but also for oligodendrocyte 
precursor cells (OPC), of which only about 50% express Cnp (Saab et al., in prepara-
tion). Thus it can be expected that virtually all mature OL express mEos2, as described 
for comparable studies of Cnp dependent transgene expression elsewhere (Belachew 
et al. 2001). Although Cnp is detectable in Schwann cells, its expression is rather 
weak, thus mEos2 expression levels may not suffice for proper analysis of peroxi-
somes in the peripheral nervous system. mEos2 positive puncta were absent from oth-
er brain cells than oligodendrocytes, but were detectable in cells of spleen and testis 
consistent with published CNP-promoter activity (Davidoff, Middendorff, Köfüncü, Mül-
ler, Ježek, & Holstein 2002b). Up to now analysis of peroxisomes in a cell type specific 
manner required time consuming colocalization studies due to high abundance of pe-
roxisomes in the brain. The mEos2 mouse significantly facilitates analysis of oligoden-
droglial peroxisomes.  
The intraperoxisomal environment had no effect on the spectral properties of the mE-
os2 fluorophore or its photoconvertibility. Exposure to high intensity ≈370 nm light re-
sulted in bright red signal with residual green fluorescence. Red fluorescence was not 
detectable in unexposed tissue or cells.  
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The conversion of the total peroxisomal population in a cell allows to monitor the rate of 
newly formed (i.e. ‘only green’) peroxisomes as well as the rate of peroxisomal degra-
dation (i.e. loss of red-labeled peroxisomes) similar to ‘pulse-chase’ experiments. Anal-
ysis of such experiments in Cnp-mEos2-PTS1 transgenic oligodendrocytes showed the 
reappearance of peroxisomes carrying only green mEos2 fluorescence already at d1 
after photoconversion, indicative of peroxisomal de novo formation. However, these 
results have to be interpreted with caution as asymmetrical or subsequent fission 
events might also result in loss of photoconverted signal by dilution. So far no experi-
mental approaches have been published that would allow a clear differentiation of de 
novo synthesis and fission under physiological conditions. Single cell analysis in CTRs 
revealed that about 40% of OLs showed an increase of photoconverted peroxisomes, 
proving that fission events can be observed in our experimental setup. Interestingly, in 
both populations of cells, those that displayed and those that did not exhibit peroxiso-
mal fission, the number of peroxisomes containing only green mEos2 fluorescence 
increased equally. 
Furthermore, instead of the whole peroxisomal pool also only a subpopulation of perox-
isomes in a cell can be photoconverted allowing to investigate the fate of single orga-
nelles. Also the import-rate of peroxisomal proteins can be investigated via measure-
ment of the green fluorescence intensity. In combination with a pulse-label approach 
measurement of intraperoxisomal fluorescence allows to compare protein import in 
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4.3 Progressive loss of oligodendroglial peroxisomes in 
tgCnpCre/Wt*Mfp2-/- mutants, but not in tgABCD1-/- mice  
The cerebral pathology of CnpCre/Wt*Mfp2-/- mutant mice shares features with 
CnpCre/Wt*Pex5-/- mice. This means that peroxisomal β-oxidation or complete peroxiso-
mal function cause a similar pathology when ablated in oligodendrocytes of mice. In 
combination with a later onset and slower disease progression in CnpCre/Wt*Mfp2-/- mu-
tants, this allows to speculate on a secondary peroxisomal defect caused by impair-
ment of peroxisomal beta-oxidation, which may reflect a complete loss of peroxisomal 
function.  
To analyze oligodendroglial peroxisomes in vivo we made use of the CNP-mEos2-SKL 
transgenic mice, which were intercrossed to CnpCre/Wt*Mfp2-/- mutants (tgCnpCre/Wt*Mfp2-
/- mice). tgCnpCre/Wt*Mfp2-/- mutants revealed an early decrease of peroxisomes in the 
brain. Already at two months of age peroxisomal number per OL was reduced by 25% 
with a progressive loss to below 50% in ≤ 16-month-old animals. Furthermore, the 
number of oligodendrocytes containing perinuclear mEos2 positive peroxisomes was 
decreased in old animals, culminating in a total loss of 2/3 of peroxisomes per area. 
The reduced number of mEos2-expressing OL may be a result of reduced detection 
caused by the dramatic decrease of the number of mEos2 positive peroxisomes. An-
other possible explanation would be oligodendroglial cell death in the brains of aged 
mutants.  
Interestingly, the reduction of the peroxisomal number was comparable between af-
fected and unaffected brain white matter, suggesting that a decrease of peroxisomes is 
not directly resulting in demyelination, but via a yet unknown additional subcellular step 
of disease. Together our observations indicate that in tgCnpCre/Wt*Mfp2-/- mice, starting 
around two month of age, peroxisomal function, beyond that of peroxisomal 
β-oxidation, might be decreased and imply an explanation for the phenotypic similari-
ties of CnpCre/Wt*Mfp2-/- to CnpCre/Wt*Pex5-/- mice. 
Another interesting finding is the pronounced reduction of the number of ‘peripheral 
peroxisomes’ in tgCnpCre/Wt*Mfp2-/- mice, i.e. peroxisomes that are not closely associat-
ed with oligodendrocyte nuclei, but reside in the cellular periphery. These are suppos-
edly located in cytoplasmic channels and other functional important sites, the paranod-
al loops of oligodendrocytes. In two-month-old animals peripheral peroxisomes were 
already reduced by half and in aged mutant only 20% were left. As this is also true for 
brain regions without overt demyelination, decrease in peripheral peroxisomes is likely 
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not due to loss of oligodendroglial structures. Instead, the increased size of mutant 
peroxisomes might complicate the transport into the cellular periphery, or the reduced 
peroxisomal biogenesis might deregulate peroxisomal transport.  
During the last 10 years the view of myelin serving only as a passive insulator has 
started to change to a more active role of myelin providing also metabolic support for 
axons (Fünfschilling et al. 2013). Peroxisomes, which are rarely found in axons, but are 
abundant in the different cytoplasmic compartments of myelin, possibly participate in 
axonal metabolic support (Kassmann et al. 2011). In this respect, the extreme loss of 
‘peripheral peroxisomes’ in tgCnpCre/Wt*Mfp2-/- - mice, might be of particular importance 
for a possible function in axonal support. Recent studies of the peripheral nervous sys-
tem of CnpCre/Wt*Pex5-/- mice showed decreased axonal conduction velocity and axonal 
swellings in the absence of demyelination (Kassmann et al. 2011; Kleinecke et al., in 
preparation). This supports the hypothesis that possibly also oligodendroglial peroxi-
somes are important for such axo-glial interactions. Furthermore it raises the question 
whether additionally to demyelination an axonal problem might add to the pathology in 
tgCnpCre/Wt*Mfp2-/-. 
cALD patients share the key features of inflammatory demyelination with patients of 
PBDs and other peroxisomal β-oxidation defects. However, the brains of aged 
tgAbcd1-/- mutants neither displayed a reduction of total, nor of peripheral peroxisomes. 
Also organelle morphology was apparently normal. Human skin fibroblast derived from 
ABCD1-deficient patients also contain normal peroxisomal numbers in contrast to 
MFP2-deficient patient’s cells (Chang et al. 1999). This observed normal appearance 
of the peroxisomal population may be interpreted such, that the ABCD1-/--related dis-
ease mechanism does not include a secondary failure of peroxisomal function as seen 
in MFP2-mutant oligodendrocytes. A second possible explanation would be, that even 
aged ABCD1-/- mice are not suitable to model the subcellular disease mechanism, 
since this mouse model also fails to show demyelination even at very old age (> 22 
months). Therefore, it would still be of interest to study peroxisomal morphology, espe-
cially of oligodendrocytes, in demyelinating lesions obtained from cALD patients to in-
vestigate, whether peroxisomal morphology is altered in a cell type specific manner. It 
is noteworthy, that such cell type-specific analysis is extremely difficult due to the high 
density of cells in myelin, and is further complicated by the invasion of astrocytes and 
microglia containing vast amounts of peroxisomes. 
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4.4 MFP2-deficiency decreases peroxisomal turnover in oli-
godendrocytes  
Human skin fibroblasts derived from patients with peroxisomal biogenesis defects show 
a dramatic decrease of peroxisome numbers along with an increase in peroxisomal 
size. The same holds true for cells with impaired peroxisomal β-oxidation, but not for 
defective α-oxidation or plasmalogen synthesis. Accumulating evidence suggests a 
role for peroxisomal β-oxidation in the control of organelle abundance. Another hint 
pointing to this direction is that overexpression of PTE1, an acyl-CoA hydrolase, which 
is thought to impair peroxisomal β-oxidation, shows a similar pattern of peroxisome 
reduction. The mechanism by which peroxisomal β-oxidation regulates peroxisomal 
abundance remains elusive so far (Chang et al. 1999).  
Our analysis confirmed a reduction of peroxisomal number also in mEos2-SKL trans-
genic mice lacking MFP2-function from oligodendrocytes. In vitro ‘pulse-chase’ experi-
ments using primary oligodendrocytes (OLs) additionally revealed prolonged detectabil-
ity of photoconverted peroxisomes implying decreased degradation of the organelles in 
tgCnpCre/Wt*Mfp2-/-. Furthermore, the formation of new peroxisomes identified by green, 
but lack of red fluorescence, accounted only for ~17% of peroxisomes in mutant cells 
compared to ~75% in control OLs.  
Current publications imply a peroxisomal fission defect in PBDs and peroxisomal 
β-oxidation disorders (Itoyama et al. 2012; Bonekamp et al. 2013). We found that 
PEX11β, which is essential for peroxisomal fission, is more abundant in myelin frac-
tions compared to total brain lysates indicating a high contribution of fission to the bio-
genesis of oligodendroglial peroxisomes (unpublished data). In this respect, oligoden-
droglial peroxisomes may be especially vulnerable to impairment of peroxisomal 
fission.    
Although it cannot be clearly differentiated, whether peroxisomal β-oxidation deficiency 
affects rather peroxisomal de novo synthesis, peroxisomal fission, or both, we meas-
ured reduced peroxisomal biogenesis, which was accompanied by increased stability 
of the organelle. Decreased peroxisomal turnover results in enhanced organelle aging. 
Aged organelles likely accumulate functional impairments as could be shown by Ivash-
chenko and coworkers, who encountered altered intraperoxisomal redox balance when 
pexophagy was impaired by 3-methyladenine treatment (Ivashchenko et al. 2011). 
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4.4.3 Direct effects of beta-oxidation impairment on fission?  
Patients’ fibroblasts with a generalized or β-oxidation-specific peroxisomal defect show 
a comparable phenotype with less abundant enlarged peroxisomes. The same applies 
for loss-of-function mutations in proteins of the peroxisomal fission machinery, like 
PEX11, which is essential for peroxisomal fission (Li et al. 2002). Interestingly, alt-
hough endogenous expression of PEX11α and PEX11β was normal, the overexpres-
sion of PEX11β led to normalization of the peroxisomal appearance proving that perox-
isome proliferation is in principal possible in mutant cells with impaired peroxisomal 
biogenesis (Chang et al. 1999). 
Another interesting observation has been reported from COS-7 cells grown in lipid-free 
and serum-free medium, which share the features of reduced peroxisomal abundance 
and increased organelle size. When PEX11β was overexpressed in these cells peroxi-
somal elongation was induced, but rare constriction and no fission, indicating a role for 
peroxisome membrane lipid composition in PEX11β dependent peroxisomal prolifera-
tion (Bonekamp et al. 2013). Itoyama and colleagues discovered that treatment with 
polyunsaturated FA particularly docosahexaenoic (DHA) and eicosapentaenoic acid 
(EPA), restored normal peroxisome numbers and morphology in human skin fibroblast 
with impaired peroxisomal β-oxidation. DHA is a highly abundant polyunsaturated FA in 
the brain whose synthesis depends on the endoplasmic reticulum and peroxisomal 
β-oxidation. DHA levels are usually strongly reduced in peroxisomal biogenesis defects 
or peroxisomal β-oxidation deficiency. A link between DHA-levels and PEX11β was 
recently shown by enhanced PEX11β oligomerization after treatment with DHA, sug-
gesting that polyunsaturated FAs interact with PEX11β to form functional complexes 
(Itoyama et al. 2012). It remains to be investigated, if reduced DHA levels are causative 
for the observed peroxisomal morphology in MFP2-deficient oligodendrocytes. Howev-
er, in contrast to data obtained from patients, DHA levels were normal even in conven-
tional MFP2-deficient mice, which was attributed to the DHA-containing chow (Huyghe 
et al. 2006).  
Besides oligomerization, also phosphorylation has been implicated to regulate Pex11β 
function. In yeast Pex11βp-phosphorylation was increased under proliferating condi-
tions, while expression of a constitutively dephosphorylated Pex11βp resulted in en-
larged peroxisomes (Knoblach & Rachubinski 2010; Joshi et al. 2012). For mammals 
no such effect of mutations in putative phosphorylation sites on the proliferative proper-
ties of PEX11β have been identified so far (Bonekamp et al. 2013). It would be of inter-
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est to investigate, whether altered peroxisomal β-oxidation possibly influences peroxi-
somal fission via altered phosphorylation states of PEX11 β.  
Furthermore, depletion of the peroxisomal fission machinery in yeast not only prevent-
ed peroxisomal fission, but also affected pexophagy providing evidence for an immedi-
ate link between biogenesis and degradation of peroxisomes (Mao et al. 2014; Mani-
vannan et al. 2014).  
 
4.4.4 Direct effects of beta-oxidation impairment on autophagy?  
Interestingly, inhibition of autophagy by 3-methyladenine (3-MA) treatment in 
tgCnpCre/Wt*Mfp2-/- OL showed not only diminished degradation, but also massively de-
creased biogenesis of peroxisomes. This constitutes an additional finding, which sug-
gests direct coupling of peroxisomal degradation and biogenesis. 3-MA acts on au-
tophagy by impeding autophagosome formation via the inhibition of PI3K (Laplante & 
Sabatini 2009). To our knowledge no effects of 3-methyladenine or its target PIK3 on 
peroxisomal biogenesis have been described. This raises the question whether abro-
gated peroxisomal β-oxidation possibly affects peroxisomal abundance indirectly via 
autophagy impairment, which in turn might decrease peroxisomal biogenesis. Interest-
ingly, peroxisomal numbers remained stable in autophagy impaired OLs in contrast to 
experiments in CHO cells, where peroxisomal number and cell size were increased 
upon 3-MA treatment. Thus control of peroxisomal abundance might be distinct in dif-
ferent cell types and possibly depends on the cells’ ability to increase their volume. In 
contrast to the similar experiments with CHO cells, mature OL did not show an in-
crease in size upon 3-MA treatment. This may suggest that regulation of peroxisomal 
abundance might be related to peroxisomal density. 
An estimated 70-80% of peroxisomal degradation occurs by macroautophagy, termed 
pexophagy, while the remaining 20-30% are supposedly degraded by 15-Lipoxygenase 
and peroxisomal LON protease (Yokota 2003; Kikuchi et al. 2004; Iwata et al. 2006). 
PEX5, the redox sensitive shuttling importer for the majority of peroxisomal proteins 
appears to play a dual role in pexophagy (Ma et al. 2013). The negative regulators of 
mTORC1, TSC1, 2, and ATM have been found to localize to peroxisomes in a PEX5 
dependent manner. Additionally, ATM kinase phosphorylates PEX5, which triggers 
subsequent ubiquitination and mediates binding to an autophagy receptor protein, to 
induce selective autophagosome engulfment (Zhang et al. 2013; 2015). It has been 
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shown that impairment of VLCFA β-oxidation leads to perturbation of autophagy-
signaling, i.e. enhanced mTORC1 activity and decreased LC3II levels, in X-ALD pa-
tients and the corresponding ABCD1-deficient mouse mutants (Launay et al. 2014). 
Treatment of human skin fibroblasts with excess C26:0, a substrate of peroxisomal 
β-oxidation, exhibited similar dysregulation of autophagic markers. Administration of a 
mTORC1 inhibitor to ABCD1-deficient mice normalized the molecular findings and alle-
viated the macroscopic phenotype (Launay et al. 2014). 
Increased cellular oxidative stress is a hallmark of peroxisomal disease (Fourcade et 
al. 2015); it causes accumulation of the PEX5 receptor on the peroxisomal membrane 
and reduces peroxisomal protein import (Apanasets et al. 2013). In our model the in-
crease of intraperoxisomal green fluorescence proves that PEX5 dependent import of 
mEos2 is not abrogated in tgCnpCre/Wt*Mfp2-/- mutant OLs. However, we cannot eluci-
date whether it is fully functional. Impaired PEX5 function in cells lacking MFP2-
function might abrogate TSC2 signaling or impede selective autophagosome engulf-
ment and cause decreased pexophagy. Co-precipitation of ATM-PEX5 or TSC2-PEX5 
and immunohistochemical analysis of ATM kinase and TSC2 localization might give 
further insight.  
Another mechanism for autophagy defects when β-oxidation is impaired might be di-
rectly linked to substrate-accumulation. In organisms with impaired peroxisomal 
β-oxidation peroxisomal substrates, e.g. VLCFA accumulate and might impair further 
cellular functions (Huyghe et al. 2006). VLCFA are frequently bound to other lipids, 
such as gangliosides and cholesterol, which require catabolic activity of other orga-
nelles (e.g. lysosomes) and possibly become non-degradable by a backlog mecha-
nism. Accumulation of gangliosides bound to VLCFA associated with a secondary im-
pairment of lysosomes was found in mutants lacking peroxisomal functions from 
Schwann cells (CnpCre/Wt*Pex5-/- mutants; Kassmann et al. 2011; Kleinecke et al., pub-
lication in preparation). Similarly, tissue of patients suffering from the peroxisomal dis-
ease X-linked adrenoleukodystrophy (X-ALD), show increased VLCFA-bound gangli-
osides (Igarashi et al. 1976). Impaired degradation of peroxisomal substrates might 
thus result in an overall autophagy impairment, not only affecting pexophagy (Lieber-
man et al. 2012). A third possibility of autophagy impairment by accumulation of 
β-oxidation substrates is highlighted by data from Koga et al., which indicate that al-
tered membrane lipid composition influences autophagosome lysosome fusion (Koga 
et al. 2010).  
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Furthermore DHA was recently observed to induce autophagy via inhibition of the 
mTORC1 pathway. Decreased levels of polyunsaturated FAs in peroxisomal 
β-oxidation defects together with accumulation of VLCFA, which possibly exert a nega-
tive effect on autophagy, may thus affect normal autophagic flux and peroxisomal fis-
sion (Kim et al. 2015; Zhao et al. 2015). 
Autophagy is crucial for proper brain function, as it prevents accumulation of cellular 
waste and dysfunctional organelles (Nixon 2013). Disrupted autophagy affects cell sur-
vival, increases oxidative stress and is likely involved in several neurodegenerative 
disorders like Alzheimer’s and Parkinson’s disease. Lysosomal storage diseases also 
show abolished autophagy (Lieberman 2012). Interestingly cerebral demyelination is a 
hallmark of lysosomal storage diseases raising the question whether impaired autoph-
agy might be responsible for demyelination in peroxisomal diseases (Cheon et al. 
2002). It remains to be investigated, whether perturbed autophagy-signaling or a sim-
ple backlog hitting lysosome function by non-degradable material are part of the 
pathomechanism also in CnpCre/Wt*Mfp2-/- mutant mice.  
The question is raised whether in MFP2-mutant cells a direct effect on peroxisomal 
biogenesis causes secondary problems in pexophagy, or vice versa inhibition of perox-
isomal β-oxidation rather causes problems in pexophagy, which lead to secondary im-
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4.5 Heterozygosity is not responsible for the pathology of 
CnpCre/Wt*Mfp2-/- mutants 
Heterozygous CNP gene dosage results in a late onset (> 24 month) mild axonal de-
generation in mice (Hagemeyer et al. 2012). Furthermore Cre expression was related 
to increased oxidative stress and peroxisome proliferation in mice (Xiao et al. 2013). To 
exclude that the reduced Cnp gene dosage or the Cre expression itself cause the ef-
fects observed in tgCnpCre/Wt*Mfp2-/- cells, Cnp-mEos2-SKL*CnpCre/WT animals with 
normal MFP2 expression were analyzed. Pulse-label experiments in OL from these 
Cnp-heterozygous mice confirmed that peroxisomal alterations were neither attributa-
ble to Cre expression nor to Cnp heterozygosity. tgCnpCre/Wt OL did not exhibit de-
creased pexophagy as observed in tgCnpCre/Wt*Mfp2-/-. Instead, these peroxisomes 
showed more proliferation compared to cells with normal CNP- and without Cre ex-
pression during the first two days after photoconversion followed by rapid peroxisomal 
degradation. The here observed, enhanced proliferation in the early phase after photo-
conversion may be attributed enhanced Cre mediated stress (Xiao et al. 2013). 
CnpCre/Wt*Mfp2-/- mutants share the key pathological features with CnpCre/Wt*Pex5-/- mu-
tant mice, which also have a reduced CNP-gene dosage in combination with Cre ex-
pression. Therefore, the finding of the much later disease onset and slower disease 
progression in MFP2-conditional mutants indicates that the pathology is indeed at-
tributable to the depletion of peroxisomal function rather than to Cnp-heterozygosity or 
Cre expression.  
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5 Material  
5.1 Antibodies  
Primary antibodies 
ACAA1      ProteinTech Group 
APP      Chemicon 
CD3      Bio-Rad 
GFAP       DAKO 
Iba      Wako 
Lamp1      BD Pharmingen 
Mac3      BD Pharmingen 
MBP      Dako 
MRP       Antibodies-online 
NeuN       Millipore 
Olig2       provided by J. Alberta Ligon et al., 2004 
PMP70     Sigma-Aldrich 
PMP70      Abcam 
 
Secondary fluorescence-conjugated antibodies 
Alexa-488     Invitrogen  
Alexa-555      Invitrogen  
DyLight 633      YO Proteins 
 
5.2 Bacterial strains  
E.coli XL1 blue bacteria   Statagene 
 
5.3 Enzymes  
SuperScriptIII Reverse Transcriptase  Invitrogen    
GoTaq Polymerase     Promega 
Red-Taq DNA Polymerase    Sigma-Aldrich    
Pfu Ultra DNA Polymerase    Stratagene 
Restriction enzymes    New England Biolabs 
T4 DNA Ligase    Promega 
DNase      Qiagen 
                                                                                                                                                    MATERIAL 
 
 63 
5.4 Chemicals and Reagents  
Standard chemicals and reagents, which are not listed separately, were purchased 
from Sigma-Aldrich and Merck unless stated otherwise.  
Agar        BD 
Agarose       BioFroxx 
Aqua Poly Mount      Polayscience Ltd.  
Aluminium sulfate       Fluka  
Bacto-Peptone      BD 
B27 Supplement       Thermo Fisher Scientific  
BSA        Pan-Biotech 
DAB        Dako Cytomation 
DAPI        Roche 
DMEM        Thermo Fisher Scientific 
dNTP´s 10 mM      Roche   
FCS        Thermo Fisher Scientific 
GelRed        Biotium 
GeneRuler 1 kb ladder     Fermentas 
GeneRuler 100 bp ladder     Fermentas 
GlutaMax       Thermo Fisher Scientific 
HBSS        Lonza 
Horse Serum       Thermo Fisher Scientific  
Paraffin        Paraplast, Leica, Germany 
Penicillin/Streptomycin      Lonza 
OptiMEM       Thermo Fisher Scientific 
Paraformaldehyde      Serva 
Lipofectamin 2000 transfection reagent   Invitrogen    
Power SYBR Green PCR Master Mix   Applied Biosystems 
Protease-inhibitor tablets (Complete)   Roche 
Sterile filters (0.45 µm)     Sartorius  
TO-PRO-3       Thermofisher 
Trypsin/EDTA (0.25%)     Thermo Fisher Scientific  
                                                                                                                   MATERIAL 
 
 64 
Trypsin       Thermo Fisher Scientific  
Yeast extract       BD 
 
5.5 Kits 
nexttecTm 1-Step DNA isolation Kit for Tissue & Cells  Invitek 
NucleoSpin Plasmid QuickPure Kit    Macherey-Nagel 
NucleoBond PC500 EF Maxi Kit    Macherey-Nagel 
QIAquick Gel Extraction     Qiagen 
RNeasy Mini Kit      Qiagen 
 
5.6 Laboratory supplies and equipment  
General laboratory equipment was purchased from Greiner Bio One, Falcon and Ep-
pendorf.  
Analytic scale AC 210 S     Sartorius  
Arium 611 Water Purification System    Sartorius 
Automated system for Epon embedding   EMPT Leica 
Biophotometer      Eppendorf 
Butterfly cannula (27G)      Venofix Nussloch, Germany 
Combi Thermosealer      Advanced 
Dispersing instrument Ultra-Turrax Polytron PT 3000  Kinematica 
Gel documentation system     Intas 
Incubator BB 6220       Heraeus 
Laminar Flow hood Lamin Air HB 2448    Heraeus 
MacMini       Apple 
Paraffin Embedding Center      MICROM HMP 110   
Peristaltic pump       Heraeus SR70 
pH-Meter       inoLab pH 720 WTW 
Pipetteboy       Integra Science  
Pipettes        Gilson 
Sliding microtome HM400     Mikrom 
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Thermo mixer       Eppendorf 
Thermocycler T3000      Biometra 
UV-Illuminator UVT 40 S/L      Herolab 
Vibratome        Leica VT 1000S, Leica  
Vortex Genie 2       Bender&Hobein AG 
Water bath        Memmert 
Micorscopes 
Axio Observer Z1 Wide-field microscope   Zeiss 
Axiophot Wide-field microscope    Zeiss 
TCS SP5 Confocal microscope    Leica 
Centrifuges 
Table top centrifuge Biofuge Pico    Heraeus 
Mikrocentrifuge       Roth 
Ultrazentrifuge XL-70      Beckmann 
 
5.7 Oligonucleotides  
All oligonucleotides were synthesized at the ‘DNA core facility’ of the Max-Planck-
Institute of Experimental Medicine. They were provided at 50 pM concentration.  
 
5.7.1 Genotyping  
CNP sense primer:   5´- GCCTTCAAACTGTCCATCTC-3´  
CNP sense primer:   5´- CATAGCCTGAAGAACGAGA-3´  
CNP antisense primer:  5´- CCCAGCCCTTTTATTACCAC-3´   
 
 
Mfp2 sense primer:   5´-CCCAACGCTGGGTCACGGATGACGG-3´ 
Mfp2 antisense primer:  5´-GCAACCATAAGTTACACAAAATGCC-3´   
 
 
Pxeos sense primer:   5´- CTTCTTACACAGGCCACCATGAGTGCG-3´  
Pxeos antisense primer:  5´- GGATCCTTACTTAGTTAAAGCTTGGATCGT-3´   
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ABCD1 sense primer: 5’-CCCTTCCTGCCACTTTCATC-3’ 
ABCD1 antisense primer: 5’-TCTCAACCTGCCCCACCTCA-3 
 
5.7.2 Cloning  
Cnp1 sense primer:  5’-CAAACAGGACATCCTTAAGAGGTG-3’ 
Cnp1 antisense primer:  5’-CATGGTGGCCTGTGTAAGAAGGGAG -3’ 
mEos2 sense primer:  5’-CTTCTTACACAGGCCACCACGAGTGCG-3’ 
mEos2 antisense primer:  5’-GGATCCTTACTTAGTTAAAGCTTGGATCGT-3’ 
 
5.8  Plasmids  
Cnp1-Cre     Lappe-Siefke et al., 2003   
pGEM-T      Promega 
pEGFP-N1     Clontech 
 
5.9 Software 
Fiji       http://imagej.net/Fiji/ 
Illustrator CS3     Adobe 
Imaris       Bitplane 
Lasergene      DNASTAR  
Office       Windows  
OS X lion      Apple 
SeqBuilder     Lasergenes 
Zen      Zeiss 
 
5.10  Molecular biology solutions 
50 x Trisacetat EDTA (TAE) Buffer  
    2.0 M   Tris-acetat, pH 8.0 
    50 mM  EDTA     
    57.1 ml  glacial acid 
fill up to 1 L with deionized H2O 
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TE Buffer   10 mM  Tris-HCL. pH 8.0 
    1 mM   EDTA  
 
 
LB Medium    0.5%  yeast extract 
    1%  Bacto-Peptone pH 7.5 
    1 %   NaCl 
 
LB Agar Plates  0.5%  yeast extract 
    1 %  Bacto-Peptone pH 7.5 
    1 %   NaCl 
    1.5 %  Agar 
Autoclave solution and cool down to 55°C 
in a water bath before adding antibiotics.  
 
5.11  Histology buffers and solutions  
 
Avertin    2%   2,2,2 Tribromethanol 99% 
2%  Pentanol 
Mixed at 40°C and stirred for 30 min, fil-
tered and stored at -20°C.  
 
16 % Paraformaldehyde 16%   Paraformaldehyde 
Heated to 65°C and stirred for 20 min in 
deionized H2O. 5M NaOH droplets were 
added until solution was cleared. The solu-
tion was then filtered and stored at -20°C 
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4 % Paraformaldehyde 10 ml  0.2M Sodiumdihydrogenphosphate  
(NaH2PO4 x H2O) 
40 ml  0.2M di-Sodiumhydrogenphosphate 
(Na2HPO4 x H2O) 
25 ml   16% Paraformaldehyde 
25 ml  deionized H2O 
 
 
Bielschowsky Silver Impregnation 
Solution A:    2.5 g   Silver nitrate  
1%   Pyridine 
in 250 ml deionized H2O 
Solution B:  I.   2.5%  Silver nitrate solution: 2.75g Silver nitrate in  
110 ml deionized H2O 
II.  65 ml  96 % Ethanol 
III. 13 ml  2.5 % NaOH  
     11 ml  concentrated NH3-Solution (32% Merck)  
 
The solutions (I-III) were joined sequential-
ly. Solution III had to be added during con-
stant stirring until the temporary brown par-
ticipate cleared.  
Solution C:   0.675 ml  40 % formaldehyde 
0.03 g   Citric acid (1 %) 
30 ml   Ethanol 
in 250 ml deionized H2O 
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Gallyas Silver Impregnation  
Incubation solution  0.1 %  Ammonium nitrate  
0.1 %   Silver nitrate  
12 ‰   Sodium hydroxide (pH 7.5)  
in deionized H2O 
The brown participate was dissolved by 
shaking. The solution was stored up to 8 
weeks.  
Solution A:  5 %   Sodium carbonate (dehydrated) in  
deionized H2O 
Solution B:    0.2 %   Ammonium nitrate  
    0.2 %  Silver nitrate 
    1 %   Wolframosilicic acid (silicotungstic acid)  
in deionized H2O 
Solution C:    0.2 %  Ammonium nitrate 
    0.2 %   Silver nitrate 
    1 %  Wolframosilicic acid (silicotungstic acid)  
    0.26%  Paraformaldehyde  
      in deionized H2O 
The physical developer was prepared 
freshly from solutions A, B and C in a 
10:7:3 ratio.  
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Haematoxylin-Eosin staining  
Mayer´s Haematoxylin solution  
 1 g   Haematoxylin  
    0.2 g   Sodium iodate  
    50 g   Potassium aluminium sulphate  
Dissolved in 1000ml deionized H2O during 
constant shaking  
    50 g  Chloral hydrate  
    1 g   Citric acid  
Eosin Solution    
Stock solution   10 g   Eosin  
    100 ml  deionized H2O 
Working solution  2.5 ml  Stock solution  
    250 ml  deionized H2O 
    12 drops  glacial acetic acid  
Scott´s solution   2 g  KHCO3 
    20 g  MgSO4 
    in 1 L   deionized H2O  
HCL-alcohol   1.25 ml  HCL 
    350 ml   Ethanol 
    150 ml   deionized H2O 
 
5.11.1 Chromogenic Immunohistochemistry  
Citrate buffer 
Stock solution A:   0.1 M  Citric acid 
Stock solution B:   0.1 M  Sodium citrate dehydrate  
Stored at 4°C 
Working solution   9 ml  Stock solution A  
    41 ml  Stock solution B  
    500 ml  deionized H2O 
Always freshly prepared 




Stock solution:   0.5 M   Tris base  
      Adjusted to pH 7.6 with HCL  
      stored at 4°C 
Working solution:   100 ml  0.5M Tris base  
    9 g  NaCl 
      in 1000 ml deionized H2O 
Always freshly prepared 
 
Washing buffer  2 %  milk powder 
      In Tris buffer  
 
Bovine Serum Albumin in PBS (PBS/BSA)  
    20 ml  0.2M Sodiumdihydrogenphosphate 
20 ml  0.2M di-Sodiumhydrogenphosphate 
1.8 g   NaCl  
1 g   BSA 
100 ml  deionized H2O 
 
Blocking buffer  20%  Goat serum in PBS/BSA  
 
Luxol- fast- blue staining  
Nuclear fast red solution 0.2g  Nuclear fast red  
    200 ml  5 % Aluminium sulfate  
Nuclear fast red was added to boiling alu-
minium sulfate and solution was further 
boiled for another 5-10 min thereafter. After 
cooling the solution was filtered immediate-
ly and again before each application.  
Staining solution  1 g   Luxol blue 
  1000 ml  96 % ethanol  
                                                                                                                   MATERIAL 
 
 72 
Ethanol was stirred and warmed while Lux-
ol blue was added. After cooling solution 
was filtered. Before use 50 µl concentrated 
acetic acid is added per 100 µl staining so-
lution 
 
5.11.2  Fluorescent immunohistochemistry 
Permeabilization solution 0.4 %   Triton X-100 in PBS  
Blocking buffer  4 %   Horse serum 
0.2 %   Triton X-100     
in PBS  
1st Antibody solution  1 %   Horse serum 
0.05 %  Triton X-100     
in PBS  
2nd Antibody solution 1 %  1.5 %  Horse serum 
in PBS  
 
5.12  Immunocytochemistry  
10 x PBS   1.7 M  NaCl 
    34 mM  KCl 
    40 mM  Na2HPO4 x 2H2O  
    18 mM  K2HPO4 
      in deionized H2O; pH 7.2 with 1M NaOH  
 
Permeabilization solution  0.1 %  Triton X-100 in PBS  
 
Blocking buffer   4 %  Horse serum in PBS  
 
1st Antibody solution  2 %  Horse serum in PBS  
2nd Antibody solution 1 %   1.5 % Horse serum  
     1:20000 DAPI or 1:5000 TO-PRO-3 in PBS  




Epon      171.3 g Glycidether 100 
     115 g  Dodecenyl succinic anhydride 
      89 g   Methyl nadic anhydride  
Components were mixed using a 
magnet stirrer for 10 min and before 
adding 6.5 ml DMP-30 and mixing 
for another 20 min. Prepare 30 min 
before embedding. 
 
5.13  Solutions and media for primary oligodendrocytes 
Modified Sato Medium  500 µl   B27 Supplement  
    250 µl  Penicillin/Streptomycin  
    250 µl   Glutamax  
    25 µl  500µM Tri-Iodo-Thyrodine  
    3.25 µl  4 mM L-Thyroxin  
Filled up with DMEM (4.5 g/L glucose, with 
natrium pyruvate, without glutamine) to 25 
ml and sterile filtered before addition 
 of 250µl horse serum. For live-cell imaging 
DMEM without phenol red was used.  
 
BME/HS    500 ml  BME 
    50 ml   Horse serum  
    1 ml   Penicillin/Streptomycin  
    1 ml  Glutamax  
 
Poly-L-Lysine    0.1 mg/ml  Poly-L-Lysine in deionized H2O 
  
5.14  Solutions for genomic DNA preparation  
 Lysis buffer   265 µl   Buffer G1 
    10 µl  Buffer G2 
    25 µl   Buffer G3 




6.1 Molecular biology methods  
6.1.1 DNA isolation and purification  
Genomic DNA preparation from mouse tissue  
Genomic DNA was purified with the ‘nexttecTm 1-Step DNA isolation Kit for Tissue & 
Cells’. Mouse tail biopsies were digested in 300 µl lysis buffer while shaking with 1050 
rpm at 62°C for 75 min. After equilibration of the columns with 350 µl Prep buffer and 
centrifugation, columns were loaded with 120 µl tail digest and centrifuged again. The 
eluate was then diluted with 800 µl deionized H2O.  
 
DNA purification  
Macherey-Nagel´s ‘NucleoSpin Plasmid QuickPure Kit’ and ‘NucleoBond PC500 EF 
Maxi Kit’ were used for small scale and large scale plasmid DNA purification, respec-
tively. The method is based on a modified protocol by Birnboim and Doly (Birnboim and 
Doly, 1979). Cells undergo alkaline cell lysis followed by SDS precipitation subsequent-
ly plasmid DNA is bound to an anion exchange resin under appropriate pH and high 
salt conditions and eluted after washing.  
Plasmid DNA was isolated from bacterial cultures grown in LB medium ON to an OD of 
2 to 3. For small scale purification 2-4 ml of the bacterial culture were pelleted and re-
suspended in 250 µl A1 buffer. Cell lysis was performed by addition of 250 µl A2 buffer 
for 5 min followed by neutralization by addition of A3 buffer. Subsequently genomic 
DNA and proteins were pelleted by centrifugation and the supernatant was loaded onto 
a column. The silica membrane was washed with 450 µl AQ buffer, dried by centrifuga-
tion and plasmid DNA finally eluted in 100 µl deionized H2O.  
For large scale plasmid purification 100 ml of bacterial culture were pelleted and resus-
pended in 4 ml S1 buffer. Cell lysis was performed by addition of 4 ml A2 buffer for 2-3 
min followed by neutralization by 4 ml precooled S3 buffer. After incubation on ice the 
solution was filtered before it was loaded onto the column that previously had been 
equilibrated with N2 buffer. After washing with 10 ml N3 buffer the DNA was eluted in 5 
ml N5 buffer and precipitated using isopropanol. The pellet was resuspended in 100 µl 
TE buffer.  
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6.1.2 DNA analysis and modification  
Amplification of DNA by polymerase chain reaction  
Polymerase chain reaction was developed by Kay Mullis (Mullis et al., 1986) and ena-
bles in vitro amplification of DNA. The amplification begins with the annealing of short 
complementary oligonucleotides, so-called primers, to the sense and antisense strands 
of the DNA defining the template region. The thermostable DNA polymerase is able to 
bind ends of double strand DNA (primer and template) and elongate the complemen-
tary strand from the 5´ to the 3´end. The first thermostable polymerase was discovered 
in Thermus aquaticus (Taq polymerase) and is widely used since. As it is a non-
proofreading polymerase it introduces about 0.8 mismatches per 1 kb amplification 
cycle. By using proofreading polymerases the mismatch rate can be reduced.  
PCR reactions consist of 3 main steps with multiple repetitions that yield an exponential 
increase of the product. Primarily DNA is denaturated at 95°C followed by primer an-
nealing at a temperature that depends on the length and composition of the primer. 
Subsequently elongation takes place at around 72°C. The time required for elongation 
depends on the length of the template as well as the polymerase used. Non-
proofreading polymerases require about 30 sec per 1 kb template where as proofread-
ing poylmerases require up to 1 min per 1 kb.  
 
Standard PCR reaction   Standard PCR Protocol  
 
 
Template (10-100 ng) X µl  1. Initial denaturation  3 min 95°C 
Sense primer (10 pmol/µl) 1 µl  2. Annealing 30 sec 56°C 
Antisense primer (10 pmol/µl) 1 µl  3. Elongation 1 min 72°C 
10 x reaction buffer  2 µl   4. Denaturation  30 sec 95°C 
dNTP mix (0.2 mM each) 5 µl  Repetition of 2-4 35 x    
Taq Polymerase (5U/ µl) 0.8 µl   5. Final annealing  1 min 55°C 
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Agarose Gel electrophoresis  
DNA molecules are negatively charged resulting in migration towards positively 
charged electrodes allowing size dependent separation. For the size separation of DNA 
fragments agarose gels with concentrations of 1-2% were used. Agarose was diluted in 
1 x TAE and heated in a microwave until the agarose was completely dissolved. The 
solution was poured into gel casting chambers and combs inserted to define pockets 
for sample loading. After cooling the gel was transferred to an electrophoresis chamber 
and covered with 1 x TAE buffer. Samples mixed 1:5 with pre-diluted GelRed (1:4000) 
were loaded next to appropriate DNA markers (100 bp or 1000 bp ladder). The voltage 
applied depended on the agarose concentration used. The separated DNA fragments 
were visualized by UV light illumination.  
 
Photometric concentration determination of nuclear acids  
According to the Lambert-Beer law the concentration of an aqueous solution is propor-
tional to its absorbance and thus can be measured by spectrophotometry. Different 
groups of molecules have individual absorption maxima. Absorbance at 260 (A260) cor-
responds to DNA, at 280 nm (A280) to protein and at 230 nm (A230) to phenol and guan-
idium whereas absorbance at 320 nm accounts for the turbidity of the sample and is 
generally subtracted from the A260 value. This allows the measurement of DNA/RNA 
concentration as well as contaminations. 
For measurement DNA was diluted 1:50 in deionized H2O in a 100 µl volume in a dis-
posable plastic cuvette and measured at the above mentioned wavelengths. For a reli-
able measurement the A260 value must lie between 0.1 and 1, the linear range of the 
photometer. Sample purity was estimated from the ratios A260/A280 and A260/A230. Good 
quality samples have a A260/A280 ratio of 1.7-2.0 and an A260/A230 ratio of greater than 
1.5.  
 
Restriction digest  
Restriction endonucleases derived from bacteria or archea recognize and cleave spe-
cific, mostly palindromic DNA sequences leaving 5´ or 3´overhangs, so-called sticky 
ends, or blunt ends depending on the enzyme. This technique enables ligation of DNA 
strands with compatible ends (preparative digest). Additionally endonuclease restriction 
with two or more endonucleases yields a specific fragment pattern helping to identify 
DNA (analytic digest). In a 20 or 25 µl volume, 500 ng to 5 µg of DNA were digested by 
1-10 U of enzyme at 37°C for 1 h. Most enzymes can be heat-inactivated at 65°C for 
20 min.  
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Agarose Gel DNA extraction  
Agarose gel DNA extraction was performed with the kit ‘QIAquick Gel Extraction’ pro-
vided by Qiagen. After DNA separation by gel electrophoresis the desired DNA frag-
ment was excised under UV light illumination. The amount of QG buffer added de-
pended on the weight of the excised agarose. The mix was incubated at 50°C for 10 
min until the agarose was completely dissolved. The solution was loaded onto a silica 
membrane washed with 750 µl PE buffer and eluted in 30 µl EB buffer.  
 
Ligation  
The formation of phosphodiester bonds between 3´hydroxyl and 5´phosphoryl groups 
of DNA with compatible ends is called ligation and can be catalyzed by a DNA ligase 
derived from the bacteriophage T4. Ligation was carried out in volume of 10 µl contain-
ing 3 U T4 ligase in buffer with vector and insert DNA in a molar ratio of 1:3. The reac-
tion incubated for 1 h at RT and was stopped at 65°C for 20 min. 
 
Ligation pGEM-T Vector  
The commercially available pGEM-T vector is a linearized vector with 3´-terminal thy-
midine overhangs allowing easy ligation with inserts flanked by adenine overhangs, so 
called TA cloning. Additionally pGEM-T contains a lacZ gene with an integrated multi-
ple cloning site as well as ampicillin resistance gene. To prepare inserts for cloning into 
the pGEM-T vector a single additional PCR step is included with the Red-Taq polymer-
ase. The Red-Taq polymerase adds a adenine to the 3´ends of the insert rednering it 
compatible to the pGEM-T vector. Ligation is carried out as described in section 
7.1.2.6.  
 
DNA sequencing  
DNA samples were sequenced at the ‘DNA core facility’ of the Max-Planck-Institute of 
experimental Medicine. 16 µl DNA sample diluted down to 100 ng/µl in deionized H2O 
were submitted for sequencing. Preexisting sequencing primers were chosen or new 
primers designed and synthesized by ‘DNA core facility’. Sequencing data was ana-
lyzed using the Lasergene EditSeq software.  
 
Primer design 
Primers were designed manually with Lasergenes SeqBuilder software and BLAST at 
NCBI. Primers had a 20 bp overlap with the template and a melting temperature of 55-
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60°C. The melting temperature was determined with the help of an online algorithm 
(http://www.basic.northwestern.edu/biotools/oligocalc.html). All primers were synthe-
sized at the ‘DNA core facility’ of the Max Planck Institute of Experimental Medicine. 
Intron spanning primers for qRT-PCR were designed using the online Universal 




Cloning of the construct for generation of Cnp-mEos2-SKL transgenic mouse 
A plasmid containing the mEos2 complete coding sequence was amplified using two 
primers. The antisense primer contained a 9 bp sequence encoding Ser, Lys, Leu for 
peroxisomal targeting followed by a stop codon and a BamHI sequence. Several ampli-
fication cycles using pfu DNA polymerase were carried out in a thermo cycler and ter-
minated with a single amplification cycle using red-taq DNA polymerase for the addition 
of 3´adenine overhang for further ligation into the pGEM-T vector via TA cloning. The 
687 bp sequence containing mEos2-SKL and a stop codon was cloned into the Cnp1-
promoter construct via the AflII and BamHI restriction sites. The final product contained 
3.9 kb, which included the Cnp promoter, 687 bp that encompassed the mEos2 coding 
sequence with the PTS1 and a SV40 PolyA sequence downstream consisting of 120 
bp. The 5.1 kb sequence was cut out via the restriction enzymes XbaI and BamHI and 
purified for microinjection into C57BL/6N fertilized oocytes.  
 
6.1.3 Transformation of chemically competent bacteria  
Chemically competent E.coli XL1 blue bacteria were thawed on ice. A fraction of the 
ligation reaction was added to 100 µl bacteria suspension and incubated for 30 min on 
ice followed by a heat shock in a water bath at 42°C for 40 sec. After another 2 min on 
ice 800 µl LB media were added and the suspension was left to rotate at 37 °C. After 
30 min varying amounts of solution were plated onto LB agar plates supplemented with 
the corresponding antibiotic. Colonies were left to grow at 37°C and single colonies 
were picked the next day to inoculated 4 ml of antibiotic containing LB medium, which 
was incubated over night and used for a small scale DNA purification.  
 
6.2 Histological methods 
6.2.1  Intracardial Perfusion  
Mice were anesthetized by intraperitoneal injection of Avertin (100µl /10 g bodyweight) 
and anesthetic depth was determined by the toe pinch-response method. After opening 
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the rip cage and dissection of the heart a butterfly cannula (27G, Venofix) was inserted 
into the left ventricle and the right atrium was incised. The animal was perfused with 50 
ml HBSS followed by 40-50 ml 4% PFA in phosphate buffer with the help of a peristaltic 
pump (Heraeus SR70, flow rate 0,2 – 0,5 ml/min). Brains were dissected and post fixed 
in the same fixative at 4°C for 4 h and then placed into 1 % PFA ON until either vi-
bratome sections were taken or further processing for paraffin embedding took place 
the following day. For epon embedding the tissue could be stored longer in 1 % PFA. 
 
6.2.2 Procedures for tissue embedding and sectioning  
Sectioning of PFA-fixed tissue 
Brains from intracardially perfused mice were post fixed over night in 1 % PFA before 
40-50 µm sections were generated with a vibratome (Leica VT 1000S, Leica Instru-
ments, Nussloch, Germany). Slices were transferred to 24-well plates containing PBS.  
 
Paraffin embedding and sectioning 
Tissues fixed with 4% PFA for at least 4 h were dehydrated in a Tissue Processor 
(MICROM HMP 110) by incubation in ethanol baths with an ascending ethanol concen-
tration followed by clearing with xylene, which ultimately was replaced by paraffin. Par-
affinated brains were embedded in 60°C paraffin in metal molds with a Paraffin Em-
bedding Station (MICROM AP280) cooled down and stored at RT. Sections (5 µm) 
were taken with a sliding microtome (MICROM HM400). For immunohistochemical 
stainings sections were deparaffinated and rehydrated by the reverse procedure as 
mentioned above.  
 
Dehydration and paraffination 
 
Procedure    Time 
50% Ethanol   1 h 
70% Ethanol   2 x 2 h  
96% Ethanol   2 x 2 h 
100% Ethanol   2 x 2 h 
Isopropanol   1 h 
Xylole    2 x 2 h  
 
Deparaffination and rehydration 
 
Procedure    Time 
60°C    10 min 
Xylole     2 x 10 min  
Xylole/isopropanol (1:1) 10 min  
100 % Ethanol  5 min 
90 % Ethanol   5 min 
70 % Ethanol   5 min 
50 % Ethanol   5 min 
deionized H2O  5min  
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Epon embedding and sectioning  
Tissue for electron microscopy imaging was osmified, dehydrated and epon embedded 
in an automated system (EM-TP, Leica). Epon was freshly prepared 30 min prior to 
embedding. After washing the fixed tissue with 0.1 M phosphate buffer the material 
was placed into the embedding machine in plastic chambers and the following program 
was carried out:  
 
Phosphate buffer   10 min, 3x  4°C 
2 % OsO4 4 h 4°C 
deionized H2O 10 min, 3x 4°C 
30 % Ethanol 20 min  4°C 
50 % Ethanol 20 min  4°C 
70 % Ethanol 20 min  4°C 
90 % Ethanol 20 min  4°C 
100 % Ethanol 20 min , 4x  4°C 
Propylenoxide  10 min, 3x RT 
Propylenoxide /Epon 2:1 2 h  RT 
Propylenoxide /Epon 1:1 2 h  RT 
 
Afterwards tissue was placed into epon filled molds and left to polymerize at 60°C over 
night. Epon embedded tissue was cut using a microtome (Ultracut S, Leica) equipped 
with diamond knives (Diatome Hist 45° and Ultra 45°C) into ultrathin (50nm) sections. 
Slices were placed on slot grids coated with Formvar polyvinyl and subsequently con-
trasted. Epon embedding and sectioning was performed by Wiebke Möbius and Bo-
guslawa Sadowski. 
 
6.2.3 Staining procedures 
Bielschowsky´s Silver Impregnation 
For visualization of axonal loss neurons were visualized by Bielschowsky´s Silver Im-
pregnation, which exclusively stains neuronal cell bodies and axons. Deparaffinated 
and rehydrated paraffin sections were incubated in 1% silver nitrate (solution A) for 30 
min at RT and dipped into ammoniacal silver nitrate solution for 10 sec (solution B) 
before they were incubated in developing solution (solution C) up to 5 sec and rinsed 
with deionized H2O. The staining was fixed by 5 min incubation in 2% sodium thiosul-
fate and sections were rinsed again in deionized H2O and dehydrated and mounted 
with Aqua polymout or Eukitt.  
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Gallyas Silver Impregnation  
Staining of myelinated fibers by colloidal silver was developed by Gallyas (Gallyas, 
1979). Deparaffinated and rehydrated paraffin sections were incubated in a 2:1 solution 
of pyridine and acetic anhydride for 30 min, washed three times in deionized H2O for 
10 min each and left in warm incubation solution for 10 min. Afterwards sections were 
washed with 0,5% acetic acid three times for 5 min and incubated in developer solution 
for 3-15 min until the staining was discernable under a light microscope. Color devel-
opment was stopped by washing in 1% acetic acid followed by washing with deionized 
H2O and fixation of the staining with 2 % sodium thiosulfate for 5 min, dehydration and 
mounting with Aqua polymout or Eukitt.  
 
Chromogenic immunohistochemistry on paraffin sections  
For chromogenic immunohistochemical stainings the secondary antibody is coupled to 
horseradish peroxidase, which oxidizes its substrate 3,3´Diaminobenzidine (DAB) 
yielding a brown precipitate. Deparaffinated and rehydrated paraffin sections were in-
cubated for 5 min in citrate buffer and then cooked in boiling citrate buffer for 10 min at 
650 W in a microwave for antigen retrieval. After cooling, sections were washed for 5 
min in Tris buffer with 2% milk powder and the slides containing sections were mount-
ed in plastic cover plates in, which the following steps were carried out. 3 % hydrogen 
peroxide was added for 5 min to inactivate endogenous peroxidases followed by block-
ing buffer for 20 min. Subsequently the primary antibody solution in PBS/BSA was ap-
plied and incubated ON at 4°C. After washing with 2% milk powder in Tris buffer the 
biotinylated secondary antibody (Dako LSAB2, solution A) was added for 10 min fol-
lowed by another washing step in Tris buffer with 2% milk and incubation in streptavidin 
conjugated horseradish peroxidase solution (Dako LSAB2, solution B) for 10 min. 
Washing with Tris buffer was performed again before the incubation with DAB sub-
strate solution (1 ml Dako substrate buffer with two drops of DAB) for 10 min. Finally a 
counterstaining with Haematoxylin was performed and the section were rehydrated and 
mounted with Aqua polymout or Eukitt.  
 
Haematoxylin-Eosin (HE) staining  
Haematoxylin staining colors nuclei dark purple while treament with Eosin results in a 
pink coloring of eosinophilic structures, such as cytoplasm and collagen. Combination 
of the dyes provides a detailed visualization of overall tissue structure. Deparaffinated 
and rehydrated paraffin sections were incubated in 0.1 % Haematoxylin for 5 min, 
washed with deionized H2O and excess dye was removed by a short dipping in HCL-
alcohol solution. For contrast enhancement sections were treated with Scott´s solution 
for 5 min before being rinsed with deionized H2O and counterstained with 0.1 % Eosin 
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for 3-5 min. After washing sections were dehydrated and mounted with Aqua polymout 
or Eukitt.  
 
Fluorescent immunohistochemistry on fixed tissue  
Vibratome sections were permeabilized in 0.4% Triton X-100 in PBS for 30 minutes. 
Blocking was performed for 30 minutes in 4% Horse serum (HS) and 0.2% Triton X-
100 in PBS. Primary antibody incubation was carried out overnight at 4°C in 1% HS 
and 0.05% Triton X-100 in PBS followed by two washing steps in PBS for 5 min. Incu-
bation in the secondary antibodies solution was performed for 2 hours in 1.5% HS in 
PBS containing either DAPI (1:20.000) or Topro (1:5000). Sections were washed twice 
in PBS and transferred to slides in tap water before mounting in Aqua Poly mount (Pol-
ysciences, Warrington, PA). 
 
Luxol- fast- blue staining 
Luxol- fast- blue stains CNS myelin in bright blue whereas neurons are stained violet 
allowing the analysis of myelinated structures as well as neuronal structures of the 
brain. Deparaffinated and rehydrated paraffin sections were incubated in 0.1 % Luxol- 
fast- blue staining solution at 56°C ON, flushed in 96 % ethanol and washed in deion-
ized H2O before incubation in 0.1% lithium carbonate for 5 min. Sections were then 
dipped shortly into 70% ethanol, washed with deionized H2O and counterstained with 
nuclear fast red for 10 min. Finally sections were dehydrated and mounted.  
 
Tissue contrasting for electron microscopy 
Grids containing the epon slices were placed with the shiny side up onto the drops of 
the following solutions for contrasting and subsequently dried with filter paper.  
4 % Uranyl acetat 30 min  
deionized H2O 1 min, 3x  
Reynolds lead citrate 6 min  
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6.3 Cell biology methods 
Preparation of cell culture media and solutions was performed in the sterile environ-
ment of a laminar flow hood. Cell cultures were kept at 37°C in a humidified incubator 
with 5% CO2.  
 
6.3.1 Preparation and culture of primary oligodendrocytes 
Brains from newborn mice (P0/P1) were prepared and transferred to a petri dish con-
taining warm HBSS. The meninges were carefully removed under a binocular together 
with the olfactory bulbus, the cerebellum, and the midbrain. The tissue was transferred 
to 15 ml Falcon tubes and 1 ml 0.25 % trypsin-EDTA in BME per brain was added for 5 
min. The trypsin-EDTA was then removed and the brain washed twice with BME medi-
um. Brains were repeatedly passed through Pasteur pipettes in a volume of 1 ml 
BME/HS per brain for dissociation of the tissue. This procedure was carried out until a 
homogenous solution was achieved. 1 ml of cell suspension was added to 14 ml pre-
heated BME/HS medium in cell culture flasks coated with Poly-L-Lysine and cultivated 
at 37°C and 5 % CO2. Three days later and then every second day medium was ex-
changed. About 7 days after plating a confluent astrocyte layer was formed, on which 
oligodendrocyte precursor cells (OPC) and microglia were growing. 10 days after, cul-
turing microglia were removed by careful agitation of the flask and exchange of the 
BME/HS medium. OPC were harvested by 30 times vigorously shaking the cell cultures 
flasks and pelleting the cells by centrifugation of the supernatant. Cells were resus-
pended in Sato medium and counted in a Neubauer chamber. Finally 50000-70000 
cells were plated in Sato medium in PLL coated 24-well plates and cultivated as de-
scribed above. For live cell imaging DMEM without phenol red was used and cells plat-
ed on 24 well plates with # 1.5 coverslips. Live cell experiments were conducted in ma-
ture primary oligodendrocytes 8 days after plating.  
 
6.3.2 Poly-L-Lysine coating  
Cell culture dishes, flasks and cover slips were coated with poly-L-lysine (PLL) for bet-
ter adherence of cells mediated by electrostatic interactions between the positively 
charged PLL and the negatively charged polysaccharide cell structures. Dishes were 
incubated in 0,1 mg/ml PLL in deionized H2O for 30 min at 37°C, washed twice with 
deionized H2O, dried and used immediately.  
 
6.3.3 Immunocytochemistry  
Cells, grown on coverslips, were washed shortly in PBS, fixed in 4% PFA for 10 min 
and washed again in PBS (3x). Permeabilization was performed for 1 min with 0,1% 
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Triton X-100 in PBS at RT followed by blocking in 4% horse serum in PBS for 30 min at 
RT. The primary antibody solution was prepared in 2% HS in PBS and added to the 
fixed cells for incubation over night at 4°C or for 1 h at RT. After washing in PBS (3x) 
cells were then incubated in the secondary antibody solution in 1,5% horse serum in 
PBS containing Dapi (1:20.000) or Topro (1:5000). After three more washing steps in 
PBS cells were dipped shortly in deionized H2O and mounted with Aqua Poly Mount.  
 
6.4 Microscopy and imaging 
6.4.1 Electronmicroscopy 
A LEO EM912 Omega (Zeiss) with on-axis 2048 x 2048 CCD camera (Proscan) was 
used. Image acquisition was carried out by Wiebke Möbius and Boguslawa Sadowski.  
 
6.4.2 Brightfield microscopy 
Chromogenic stainings were analyzed with a Zeiss Axiophot microscope controlled by 
the Zen software and equipped with a AxioCamMRc3 camera. Single or tiled images 
were acquired with Plan-Neofluar 20x/0.50 objective or a EC Plan-Neofluar 40x/0.75 
objective and subsequently stitched and corrected for shading inhomogeneities in the 
Zeiss Zen software. Images were exported in the .tiff image format and analyzed in 
FIJI.  
 
6.4.3 Epifluorescence microscopy  
Setup 
A Zeiss Observer Z1 inverted microscope controlled by the Zen software and equipped 
with a 12-bit AxioCamMRm3 camera was used for the analysis of fluorescently labeled 
samples. A mercury arc lamp (HXP 120 V) served as a light source that was filtered by 
the following filter cubes accommodated in a motorized filter turret. Dapi was visualized 
with a 365/50 nm band pass excitation filter, a 395 nm dichromatic mirror, and a 445/50 
nm band-pass emission filter. EGFP, green mEos2, Cy2 and Alexa 488 were visualized 
with a 470⁄40 nm band pass excitation filter, a 495 nm dichromatic mirror, and a 525/50 
nm band pass emission filter. Cy3, Alexa 555 and red mEos2 were visualized with a 
545/25 nm band pass excitation filter, a 570 nm dichromatic mirror, and a 605/70 nm 
band-pass emission filter. Cy5, Alexa 633 and Topro-3 were visualized with a 640/30 
nm band pass excitation filter, a 660 nm dichromatic mirror, and a 690/50 nm band-
pass emission filter. An adjustable rectangular diaphragm in the light path allowed the 
control over the size of the field of illumination. Cellular structures were visualized with 
a Plan-Neofluar 20x/0.50 objective and subcellular structures with a C-Apochromat 
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63x/1.20 W Korr UV VIS IR objective. The microscope was equipped with an incuba-
tion chamber and controlled for temperature, CO2 and humidity.  
 
Image acquisition: Embedded samples  
For quantitative analysis of fluorescence signals the metal halide lamp was warmed up 
20-30 min prior to use. The exposure was set manually for each staining such that at 
least 25% of the cameras dynamic range were covered. Samples that were to be com-
pared were imaged on the same day and with the same parameters. For deconvolution 
3D images were collected matching Nyquist criteria. Non-uniform illumination was cor-
rected and shading correction performed in Zen before image export in the .czi format. 
For peroxisome quantification on brain vibratome sections a Z-stack spanning 3.2 µm 
was acquired and analyzed in Imaris. For figures in section 3.3.1 and 3.3.2 a 6.4 µm 
spanning Z-stack was acquired with subsequent deconvolution in the Zen program and 
final adjustment steps in Fiji. Pictures were analyzed in Fiji or Imaris.  
 
Image acquisition: Live-cell imaging  
Preincubation of the microscope was started 2-3 h before image acquisition to fully 
equilibrate the system and avoid drift. Temperature was kept at 37°C and air was hu-
midified and enriched with 5% CO2. A C-Apochromat 63x/1.20 W Korr UV VIS IR ob-
jective was used for all live cell experiments. To lower possible phototoxic effects ex-
posure times were kept to a necessary minimum and 3D images were under sampled 
along the Z-axis with 0.5 µm distance between each image. The rectangular diaphragm 
restricted the light reaching the sample to the field of view of the camera. Only a maxi-
mum of 20 positions per well were imaged to lower cell media exposition to light and 
thus generation of reactive oxygen species. A dark field picture was acquired and au-
tomatically subtracted from the final image to eliminate hot pixels. For photoconversion 
of mEos2 the rectangular diaphragm was set to either allow illumination of the whole 
cell or just a small region of interest and the sample was illuminated with ultraviolet light 
for 1200 ms at 100% lamp output. Green mEos2 was imaged at 150 ms and red at 450 
ms. Images were stitched, saved in the .czi format and further analyzed in Imaris.  
 
6.4.4 Nanoscopy 
Super resolution images by stimulated emission depletion (STED) were acquired on a 
homebuilt STED microscope equipped with a 63x glycerol immersion objective (Leica 
HCX PL APO 63x / 1.3) in collaboration with Katrin Willig. Details of the setup are de-
scribed elsewhere (Willig et al., 2014). mEos was excited at 480 nm with a pulsed di-
ode laser and 595nm STED light was provided by an optical parametric oscillator 
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(OPO, APE, Berlin) pumped by a mode-locked Ti:Sapphire laser (Maitai, Spectra Phys-
ics) at a repetition rate of 80 MHz. The doughnut shape of the excitation beam was 
achieved by a vortex phase plate. PFA fixed brain sections were taken with a vi-
bratome from Cnp-mEos2-PTS1 control and mutant mice and mounted in Aqua Poly 
mount. 5 stacks of images were acquired with a pixel size of 29 nm in x and y and a 
pixel dwell time of 20 µs, 500 nm apart in z. The resolution was ≤ 80 nm.  
 
6.4.5 Magnetic resonance tomography  
Mice were primarily anesthetized with 5 % Isoflurane and subsequently intubated and 
artificially ventilated with 1.75 % Isoflurane. The animals were secured in a reproduci-
ble position and the body temperature was kept at 37°C by a heated water blanket. The 
resolution was 117 µm. All measurements were conducted by Dr. T. Michaelis in the 
Biodemedizinische NMR Forschungs GmbH at the Max-Planck Institute for biophysical 
chemistry.  
 
6.5 Image processing  
6.5.1 Fiji  
Chromogenic images were quantified using the FIJI software. APP and CD3 stainings 
were counted manually with the multi point tool. The Mac3 positive area was quantified 
automatically after performing color deconvolution and thresholding.  
In fluorescent images thresholding was performed with the auto local contrast function 
and fluorescently labeled areas were measured automatically. Calculations were per-
formed in Microsoft Office Excel.  
For publication a maximum intensity projection of deconvolved or undeconvovled Z-
stacks were conducted and fluorescence adjusted for better visualization. 
 
6.5.2 Imaris 
Peroxisome quantification was carried out in Imaris. 2D stacks were reduced to one 
plane by maximum intensity projection. The spots wizard was used to count peroxi-
somes and determine intraperoxisomal fluorescence. In Live-cell imaging experiments 
green and red peroxisomes were quantified automatically. Only green peroxisomes 
were calculated by the subtraction of red peroxisomes from green peroxisomes. For 
analysis of the peroxisomal size in images acquired by STED microscopy the Surfaces 
wizard was used with the region growing option enabled. The percentage of Olig2-
positive cells expressing mEos2 was determined by generation of mEos2-positve spots 
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and Olig2-postive surfaces and colocalization of the same. In Cnp-mEos2-PTS1 trans-
genic animals crossbred to Cnp-Mfp2 mutants peroxisomes were quantified by the 
spots wizard. Oligodendrocytes were defined as Topro positive nuclei surrounded by 
mEos2 positive peroxisomes. Peroxisomes further than 4 µm away from an oligoden-
drocyte nucleus were identified by the ‘Spots close to surface’ function and were de-




Deconvolution was conducted in the Zen Software. A fast iterative default mode was 
applied. 
 
6.6 Animals and behavior 
All mice used in this study were bred and maintained in the animal facility of the Max 
Planck Institute of Experimental Medicine. Animal maintenance, handling and experi-
ments were in compliance with the German animal welfare laws and regulations. Best 
efforts were made to reduce animal suffering as well as animal numbers used for ex-
periments. Food and tap water were available ad libitum. Mice were kept in standard 
cages (Makrolon Type2, 19 x 34 x 20 cm). The room temperature was kept at 22±1 °C 
and the 12/12 h day and night cycle was kept constant with light on from 4.30 am till 
4.30 pm. Animals were sacrificed by cervical dislocation for fresh tissue collection or 




For the evaluation of the overall condition of the mutants, mice were observed for pres-
ence (+) or absence (-) of altered fur appearance, kyphosis, ataxia, tremor, passive-
ness and hindlimb paralysis. Fur appearance, tremor and passiveness could best be 
judged by the monitoring of cage behavior. Atactic gait was analyzed by observation of 
the hindlimbs while the mouse was moving on a flat surface. An overall score was cal-
culated for each mouse.  
For a more detailed analysis of ataxia the grid test and the beam test were conducted. 
For the grid test mice were placed on a metal grid with a spacing of 1 cm2 in between 
the rods, which measured 2 mm in diameter. Mouse movement was observed for a 
distance of about 80 cm and slips counted. The test was repeated three times for each 
animal. The beam test consists of a 1.5 cm broad and 55 cm long elevated beam that 
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terminates in a hiding box. Mice were placed at the end of the rod and were observed 
until they reached the hiding box. The number of slips were assessed in three repeats 
per mice.  
 
6.6.2 Generation of transgenic Cnp-mEos2-PTS1 mice 
Purified transgenic DNA prepared as described in section 6.1.1 was used for mi-
croinjection into C57BL/6N pronuclei. Microinjected oocytes were then transferred to 
pseudopregnant mice. The procedure was performed at the transgenic facility of the 
Max Planck Institute of Experimental Medicine. Tail biopsies from 3 week old offspring 
were used for DNA preparation and genotyping to identify potential founder mice.  
 
6.6.3 Generation of CnpCre/Wt* Mfp2-/- mice  
Transgenic Mfp2loxP/loxP animals were a generous gift from Myriam Baes and have been 
described before (Verheijden et al. 2013). Generation of mice containing MFP2-
deficient peroxisomes in myelinating glia cells was achieved by cross-breeding 
Mfp2loxP/loxP to Cnp-Cre transgenic mice (Lappe-Siefke et al. 2003). Mfp2flox/flox mice 
were used as controls.  
 
6.6.4 Genotyping of transgenic mice  
Tail biopsies were taken at the age of 3 weeks and DNA was prepared as described in 
section 6.1.1. The genotype was determined by PCR containing mutant specific geno-
typing primers. All genotyping primers were synthesized at the ‘DNA core facility’ of the 
Max Planck Institute of Experimental Medicine. They were provided at 50 pM concen-
tration and diluted 1:5.  
Cnp-mEos2-PTS1 genotyping 
PCR reaction mix        PCR program   
1 µl  DNA  1. 95°C 3 min 
0.4 µl  Genotyping forward primer  2. 60°C 30 sec 
0.4 µl Genotyping reverse primer  3. 72°C 1.5 min  
2 µl dNTP mix (2 mM)  4. 95°C 30 sec 
4 µl 5 x buffer  5. 50°C 1 min 
0.1 µl go Taq polymerase (1U/µl)  6. 72°C 10 min  
13.1 µl  deionized H2O  7. 4°C  pause  
   2 to 4: 34 cycles  
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CnpCre/Wt* Mfp2-/-  genotyping  
Mfp2 flox/flox genotyping  
PCR reaction mix           PCR program   
1 µl  DNA  1. 95°C 3 min 
0.5 µl  Genotyping forward primer  2. 65°C 1 min 
0.5 µl Genotyping reverse primer  3. 72°C 1 min  
2 µl dNTP mix (2 mM)  4. 95°C 1 min 
4 µl 5 x buffer  5. 65°C 1 min 
0.1 µl go Taq polymerase (1U/µl)  6. 72°C 10 min  
12.9 µl  deionized H2O  7. 4°C  pause  




Cnp-Cre genotyping   
PCR reaction mix           PCR program   
1 µl  DNA  1. 95°C 3 min 
0.5 µl  Genotyping forward primer  2. 50°C 30 sec 
0.25 µl  Genotyping forward primer  3. 72°C 1 min  
0.75 µl Genotyping reverse primer  4. 95°C 30 sec 
2 µl dNTP mix (2 mM)  5. 50°C 1 min 
4 µl 5 x buffer  6. 72°C 10 min  
0.1 µl go Taq polymerase (1U/µl)  7. 4°C  pause  





6.7 Data analysis  
For histological analysis the mean of the technical replicates of each sample was com-
bined to one data point. N-numbers reflect biological replicates. For live-cell imaging at 
least 10 cells per condition were analyzed and n-numbers reflect independent experi-
ments. Data analysis was conducted in Microsoft Excel 2011. Data is presented as 
mean + standard deviation (SD). Statistical significance between two groups was de-
termined by the unpaired Student´s t test assuming normal distribution between sam-
ples. P-values smaller than 0.05 were considered significant. P-values < 0.05 are dis-
played with (*), < 0.01 with (**) and <0.001 with (***).   
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